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Summary  
 
Aralar, a mitochondrial aspartate/glutamate carrier (AGC), belongs to the family of Calcium 
mitochondrial carriers (CaMC) and is a component of the malate-aspartate  NADH shuttle 
(MAS). It has been shown essential for proper mitochondrial function [1]. 
Having in mind that differentiating neurons have increasing energetic demands, that 
differentiating neurons produce elevated levels of reactive oxygen species (ROS), which 
could expose mitochondria to an increased stress[2], and that the MAS shuttle function could 
be implied in differentiation and survival abilities of cells[3], the matter arises whether Aralar 
could be relevant for cell differentiation and/or survival capacity.   
In this thesis Aralar´s eventual role in dopaminergic neurogenesis was investigated. 
 Expression studies, using immunohistochemistry of ventral mesencephalon (VM) cryostat 
slices, immunocytochemistry of ventral mesencephalic (VM) primary culture and mES cells 
and western blot methods, carried out in CD1 wildtype mice showed abundant Aralar 
expression during critical phases of dopaminergic neurogenesis.  
Comparative in vivo immunohistochemical and in vitro immunocytochemical expression 
studies of VM at embryonic ages E11.5, E13.5, e14.5 and E15.5 of WT(+/+) and KO (-/-) 
aralar mice revealed differences in dopaminergic neuron harvest (evaluated by tyrosine 
hydroxylase expression) and expression differences of Foxa2, a dopaminergic transcription 
factor, as well as the cell cycle marker Ki67 and the apoptotic marker casp3. Therefore an 
impact of Aralar on cell survival capacity due to missing mitochondrial integrity is suggested. 
Furthermore MAS shuttle activity deprivation could explain metabolic changes which could 
influence transcriptional control of dopaminergic neurogenesis.  
Moreover mES cell lines from aralar (+/-) mates have been established and characterised. 
Pluripotency of established lines has been approved by immunocytochemistry and 
cytochemistry. Still genotyping, antibiotic selection and western blot analysis demonstrated 
that no ara (-/-) mES cell line could be derived. This lead to the conclusion that Aralar might 
already be implicated at a very early point of development maybe because of restricted 
energy supply. Aralar deficiency at blastocyst stage might difficultate their detection.   
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1. Introduction 
 
1.1. Parkinson 
 
The illness of Parkinson (PD) was first described by James Parkinson (Parkinson, 1817). 
Affected individuals show an accumulation of the following symptoms of complex motor 
activities:   1. rhythmic tremor 
2. loss of control of voluntary movements (Akinesia) or deficiencies in 
the start of those (slow movements, bradykinesia) 
   3. muscular rigidity 
   4. instable posture 
5. later symptoms like dementia [4, 5] 
These symptoms are caused by the selective cerebral loss of dopaminergic neurons (DAns) 
localized in the pars compacta of the substantia nigra (SNpc). As a consequence the relative 
level of the neurotransmitter dopamine is reduced in its target regions which are the striatum 
(nucleus caudatus/putamen), the cortex and the nucleus accumbens.  
Various treatment options for PD do exist including pharmalogical treatment, deep brain 
stimulation, cell replacement strategies etc.. Pharmalogical treatment aliviates the symptoms 
to a certain extend but prolonged administration can result in severe side effects. Deep brain 
stimulation targeting the subthalamic nucleus can bring ease  but is only appropriate and 
efficient for a reduced number of patients 
Cell therapy for PD tries to diminish the illnesses symptoms, by subjecting cells in vitro a re-
/de-/differentiation program, for obtaining DAns, which are able to integrate at the place of 
axonal degeneration and to establish contact with the target cells thereby re-establishing 
neurotransmission.  
Human foetal tissue has been used demonstrating some clinical efficacy [6] still it confronts 
us with problems like being not expandable  or being difficult to standarize regarding tissue 
composition, quality and viability [7] aside from ethical restrictions.  
These severe limitations demand for alternative cellular sources. In this regard stem cells in 
general and mainly embryonic stem cells provide an unlimited source of cells.  
Embryonic stem cells (ESCs) are derived from the inner cell mass of blastocyst and are 
characterized by their extensive selfrenewal capacity and their potential to differentiate into 
any cell type of the body, including neuroepithelial tissue and specific neuronal cells [8-10].   
It has already been possible to generate cells with mDAn phenotype from mES cells of which 
the developmental program in vitro recapitulates the temporal course of normal mDAn 
maturation [11] [12] [13-15].  
However there are three major challanges that still have to be overcome:  
Firstly sufficient quantities of differentiated cells of the desired type have to be achieved.  
Secondly so far only poor post graft survival has been achieved in animal models 
transplanting ESCs [11, 15-19]. 
When it comes to human embryonic stem cells (hESCs) the cell harvest of graft survivers is 
even worse even under immunosuppression treatment in the murine model of PD [17, 20]. 
Thirdly phenotype heterogenity leading to teratoma formation has to be diminished [21, 22]. 
Moreover, as grafts, also to the formerly immunologically previleged thought system, the 
brain, are allogenic,  at the moment accompanying immunosupression treatment is 
indispensable for graft survival. hESCs banking or nuclear transfer as well as induced 
pluripotent stem cells (IPs) could be used as an alternative to reduce disparities between 
donor and recipient in a future.  
 
1.2. Midbrain dopaminergic (mDA)  neuron development in mice [23] 
 
Midbrain dopaminergic neurons (mDAn) are present in two areas of the adult mouse brain: 1. 
the substantia nigra pars compacta (SNc or A9 group) and 2. the ventral tegmental area 
(VTA or A10 group). These two neuron populations have different projection sides wich also 
correspond to different functions. SNc projects to the dorsolateral striatum and regulates 
motor functions and the VTA projects to the ventromedial striatum and cortical areas is 
thereby contributing to the mesocortical limbic system and regulating emotional behaviour 
and mechanisms of natural motivation and reward.  
 
 
1) Fig. 1: Dopaminergic neurons in the CNS 24.  
Schematic illustrating the location of Th+ neurons, corresponding to A8-A15 groups, in mouse brains ranging 
from E12.5-E14.5. The DA groups (light blue areas) are depicted in relation to the neuromeric map 
[subdivision into transeverse segments25 and the alar (dorsal) and basal (ventral) plate subdivision. 
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Looking chronologically at SNc mDAn development one can figure out three major  
transitions which are influenced by diffusable factors secreted by signaling centers as well as 
cell intrinsic factors within the progenitors[24, 25]   
(1) Regionalisation of neural plate before ~E9 (progenitors) 
 (2) Midbrain cell fate determination ~E9 to E11 (immature mDAns) 
 (3) Terminal differentiation ~E11 onwards ( mature mDAns) 
During regionalisation two axis of the neural plate can be made out: the anterior posterior 
(a/p) and the dorsal ventral (d/v) axis. During neurulation a tube is formed in which the neural 
plate midline occupies the ventral-most side of the evolving nervous system, receiving 
extrinsic signals from the underlying mesoderm and signals from within the neural plate itself.  
During early regionalisation the midbrain-hinbrain border (mhb) also called Isthmic Organizer 
is established, defining a spatial seperation along the a/p axis. Fgf8 expression and a 
corepressive interplay of Otx2 and Gbx2 maintain the position of this signaling center. Within 
the mhb signaling factors Wnt and En1/2 are induced for proliferation and survival of the VM 
cells. Sonic hedgehog (Shh) is responsible for patterning along the d/v axis being induced by 
extrinsic Shh signaling from the underlying notochord. It is expressed only in the most ventral 
population, giving rise to the mDAn. Endogenous lateral Otx2 expression seems to restrict 
Shh expression to the ventral domain thereby preventing the Shh inhibition of lateral Nkx6.1 
expression zone, which generates red nucleus (RN) progenitors.  Within the later Nkx 6.1 
expression zone emerges a narrow band of Nkx2.2, which later gives rise to GABAergic 
neurons [26].  
mDA progenitors are derived from radial glial like floor plate cells, which means that at a 
certain point they have to accomplish a switch to neuronal fate maybe by expression of 
proneural genes like Ngn2 or Mash1[27] [28]. 
The developing neuroepithelium of the midbrain (mb) proliferates, thereby getting thicker and 
is getting layered. The ventral ventricular zone cells maintain their proliferative neural stem 
cell character while other cells differentiate further, start to migrate laterally and ventrally and 
exit the cell cycle. The laters start to express Lmx1a, Foxa2, lmx1b, Msx1/2, Ngn2 and at 
early stages keep on expressing Shh. Shh induces Lmx 1a expression (E9). Cells that 
downregulate Shh at a later stage still seem to be capable of giving rise to mDAn progenitors 
if they continue to express Lmx1a. Msx1 acts synergistically with Lmx1a inhibiting Nkx6.1 
lateral expression allowing thereby Ngn2 proneural gene expression. Ngn2 mediates 
transition from the proliferative zone to the intermediate zone, where cells start to express 
Nurr1 (E10.5). 
Foxa2 influences Ngn2 and later on proper Nurr1 and En1 expression in a dosage 
dependent manner. [29] 
 
Mash1 which coexpresses with Ngn2 is  not required for mDA neuron development, but  it is 
able to compensate partially Ngn2 function in mDA progenitors [27].  
 
For obtaining the final characteristics of mDAn the progenitors start to express TH, the rate 
limiting enzyme for dopamine (DA) production, and aromatic L-aminoacidic decarboxylase 
(AADC). These cells also specifically express En1/2, which seems to be crucial for the 
maintenance of neurons of the SNc but not of the VTA. It is believed that ventrolateral cells 
go on to form the SNc and more medial ones give rise to the VTA. Pitx3 is required for SNc 
cell maintenance but not for VTA. Lmx1b expression becomes restricted to mDAns of the 
mb. 
 
 
2) Fig. 2: Molecularly distinct DA cell populations in the mouse ventral midbrain.24  
(A, part a) An E12.5 mouse embryo. The black line marks the plane of section shown in the image to the 
right. (A, part b) An enlarged view of the ventral midbrain (square box in A, part a), illustrating the position 
occupied by mitotic progenitors, immature and mature postmitotic neurons of the mDA lineage. (B) The 
sequential timing of transcription factor activation and defined marker expression in mDA progenitors. The 
curved arrow indicates cycling cells. (C) The timing of expression of transcription factors in mDA progenitors 
(not in subsequent steps of the lineage) are shown. Dotted lines indicate that the precise timing of expression 
shutdown has not been determined.  
   
 
Functional maturation of mDAns takes place by extension of axonal and dendritic processes. 
This process starts at E11 when mDAn axons project rostrally. By E14.5 many of them have 
reached their targets (mainly the striatal cells) [30]. Guidance molecules such as the 
homeodomain proteins En1 and En2 are proposed to be implicated in this process as also in 
the induction of guidance molecule receptors expression like Ephrin-A2 and Ephrin A5. Slits 
and Netrins may also be involved in target recognition by nigrostriatal mDAns [31]. Upon 
target innervation, mDAn axons likely compete for establishing synapses and for survival. 
Growth factors, notably GDNF and BDNF, are implicated in this process [32].  
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1.3. Aralar  
 
Aralar as well as its isoform Citrine are mitochondrial carriers located in the inner membrane. 
They belong to the calcium mitochondrial carriers (CaMCs)  family, which have N-terminal 
extensions harbouring a number of EF-hands the archetypical Ca2+-binding motifs. Within 
this group they belong to the subgroup of apartate/glutamate carriers (AGC) being members 
of the malate-aspartate NADH shuttle (MAS). Aralar is encoded by a gene on chromosome 
2q31 [33] and Citrin on chromosome 7q21 [34].  
 
 
3) Fig. 3: Secondary structure of calcium-binding mitochondrial carriers36. 
In both CaMCs, the carboxy-terminal half corresponds to the MC homology region, and the N-terminal 
extension harbors Ca2+-binding EF-hand motifs. The MC homology region, about 300 amino acids long, is 
represented according to its homology with that of adenine nucleotide translocase in its 
carboxyatractylosidebound form37. TM1-6 corresponds to the six tilted transmembrane helices characteristic 
of all MCs, three of which are kinked (1, 3, and 5 because of the presence of conserved prolines. Three 
shorter helices in the loops between TM 1-2, TM 3-4, and TM 5-6 face the matrix and are parallel with the 
membrane surface. The MC region forms a basket opening to the intermembrane space, with a funnel-
shaped cavity inside that ends on a narrow pit close to the matrix surface 37. The N-terminal extensions of 
AGCs are longer than those of SCaMCs, and the overall distribution and sequence of EF-hand motifs is 
unrelated to that of SCaMCs, which are very similar to calmodulin. 
 
The transport reaction catalysed by the AGCs is the only irreversible step in the malate-
aspartate shuttle and a main point of regulation. Aralar exchanges matrix aspartate for 
external glutamate plus a proton. The major route of aspartate production in the central 
nervous system is thought to be mitochondrial and it depends on Aralar for aspartate efflux to 
the cytosol. In the cytosol NADH is produced during glycolysis and shuttled into mitochondria 
by MAS. Blocking of MAS gives a hold on glycolysis, which can lead to energy deprivation of 
the cell [35].  
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4) Fig. 4: Ca2+ activation of the aspartate-glutamate carrier (AGC)–malate–aspartate NADH shuttle 
pathway (aralar–MAS)36  
and the calcium uniporter–mitochondrial dehydrogenases pathway (CaU–mitDH) by calcium. The MAS is 
made up of four enzymes, mitochondrial and cytosolic aspartate aminotransferases (AST) and malate 
dehydrogenases (MDH), and two mitochondrial carriers, the AGC and the a-ketoglutarate–malate carrier 
(OGC). MAS activity results in the transfer to the mitochondria of reducing equivalents generated with the 
reaction of glyceraldehyde-3-phosphate dehydrogenase (1). Extramitochondrial Ca2+  can activate the aralar–
MAS pathway, resulting in increased mitochondrial NADH, underlined. Mitochondrial matrix Ca2+, taken up 
through the Ca2+  uniporter (CaU), activates pyruvate dehydrogenase, PDH (2), isocitrate dehydrogenase, 
IDH (3), and a-ketoglutarate dehydrogenase, a-KGDH (4), generating intramitochondrial NADH, in not 
underlined. 
 
Aralar and Citrin have an overlapping distribution in embryogenesis. In fact, abundant 
expresssion of both isoforms can be observed in brain (including midbrain) of E11 mouse 
embryos [36].  
In the adult brain only Aralar is present and Citrin gets restricted to the rest of the body 
beeing implicated also in the urea cycle. Aralar is mainly expressed in neurons in comparison 
to glial cells and this Aralar expression augments with neuronal maturation.  
Deficiency of Aralar (in KO mice) induces a dose dependent decrease in mitochondrial 
activity (or dysfunction of mitochondria) in brain, mainly in neurons and in skeletal muscle 
leading to death 20 days postnatal [1].  
These knock out mice have also allowed the discovery of new functions of aralar: 1) it is 
required for synthesis of brain aspartate and N-acetylaspartate, a neuron-born metabolite 
that supplies acetate for myelin lipid synthesis in the brain and 2) it is essential for the 
transmission of small Ca2+ signals to mitochondria via an increase in mitochondrial NADH 
[37].  
 
1.4. Evidence for possible Aralar implication in mDA neuron   
developement and pluripotency  
 
Mitochondria not only have a key role in electron transport and oxidative phosphorylation, 
they  are also the main cellular source of free radicals and  are  involved in calcium 
homeostasis and in the regulation of cell-death pathways [38]. 
 
 
19
 
 
20
Multiple lines of evidence suggest a pathogenic role of oxidative damage and mitochondrial 
dysfuncion in PD  [39].   
Cellular ability to regulate Reactive Oxygen Species (ROS) levels and respond to oxidative 
stress levels will in part be determined by the volume and efficacy of mitochondrial mass. 
[40]  
Pluripotency seems to be associated with anaerobic metabolism and a poorly developed 
mitochondrial network. Differentiation leads to activation of mitochondrial biogenesis 
according to the metabolic requirements of the specific cell type[41]. 
Mitochondrial dysfunction and the thereby caused lack of sufficient energy supply at 
such an early state of development could deprive cells drastically in their capacity of 
differentiation and therefore in their ability to give rise to dopaminergic neurons.  
Hematopoietic stem cells (HSC) and  neural stem cells appear to show low ROS levels 
compared to more mature cells [2]. Therefore one could conclude that pluripotent cells 
produce little ROS species, which changes upon differentiation.  
It is likely that dopamine and its metabolism, which generates reactive oxygen species, place 
an additional burden on dysfunctional mitochondria, thus accelerating neuronal loss. 
Alternatively, functionally compromised mitochondria may result in early defects in 
neurotransmission, resulting in an imbalance of cytosolic dopamine in the longterm, which 
could be neurotoxic (more than other neurotransmitters) [3] and dedifferentiation [42, 43].  
In the case of Aralar deficiency the more vulnerable mitochondria might render the cell 
less competent to deal with higher ROS levels.  
 
All the above data demanded for an analysis of the role of these carriers played during 
pluripotent state and midbrain dopaminergic neuron differentiation, development and 
survival. 
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2. Hypothesis of this diploma thesis 
 
a) Given that differentiating neurons have increasing energetic demands Aralar could 
influence the process of dopaminergic neural and neuronal differentiation, due to its 
importancy for mitochondrial integrity.   
 
b) Pluripotent cells seem to produce relatively low levels of ROS. Once they start 
differentiating ROS production rises. More fragile mitochondria of Aralar deficient 
mice might be limited in their capacity to deal with higher ROS levels.  
 
c) Considering the function of Aralar as the major aspartate supplier for the cytosol in 
brain neurons, increased Aralar expression with neuronal maturation supposes that 
its deficiency carries out its effects at a later point of embryonic development as 
to say from when neurons reach maturity onwards.  
 
3. Objectives of this diploma thesis: 
 
a) Technical set up of cryostat cutting, immunohistochemical and immunocytochemical 
techniques, optimizing the derivation of primary culture, their culture conditions and 
optimizing MEF feeder cell derivation as well as blastocyte derivation. 
b) Comparative in vivo immunohistochemical expression studies of different 
characteristic dopaminergic markers as well as cell cycle markers in coronal brain 
sections at 3 stages of dopaminergic neuron evolution (E11.5,E13.5,E15.5) of 
WT(+/+) and KO (-/-) Aralar embryos.  
c) Comparative in vitro immunocytochemical expression studies of characteristic 
dopaminergic markers as well as cell cycle markers in primary culture of E12.5,E13.5 
and E14.5 neural dopaminergic precursors of the ventral mesencephalon of WT(+/+) 
and KO (-/-) Aralar mice  
d) Derivation mES cell lines from blastocytes of E3.5 HET(+/-) mated Aralar mice. 
Comparative in vitro immunocytochemical, cytochemical and Westernblot expression 
studies of these lines regarding their pluripotency and their differentiation capacity 
towards a dopaminergic fate.  
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4. Materials and Methods: 
 
4.1. Immunochemistry Buffers and solutions:  
 
PB 1L 0.2M pH 7,4  
Solution A: 0.2M 
NaH2POH2O Mw=137.99 g/mol 
27.598 g/1000 ml  6.9 g/259 ml 
Solution B: 0.2M base 
Na2HPO412H2O Mw= 358.14 g/mol 
71.628g/1000 ml  57.36 g/800ml  
pH was adjusted  by adding solution B to solution A  
 
PBS: 1 L 1x pH 7.4 
PB 0.2M 50 ml  
NaCl  8.76 mg 
KCl  200 mg 
H2O  950 ml  
 
Blocking solution:  
10% serum (horse, goat or chicken) 
0.25% Triton 
PBS 1x 
 
Master mix (working solution) 
1% serum (horse, goat or chicken) 
0.25% Triton 
PBS 1x 
 
Moviol/Dabco:  
6g of glycerol were mixed with 2.4g of moviol (Calbiochem Ref.475904, Polysciences Ref. 
17951) in a 50ml centrifuge tube containing a rotation magnet. During mixing 6 ml of MiliQ 
H2O were added and the solution was incubated for 2 hours at room temperature. Then 12ml 
of 0.2M Tris pH8.5 and 230 µl of Thimerosal 1% (weight/volume in H2O) were added.  
Then another 10 minutes of incubation at 50°C followed moving the tube continuously until 
all the moviol was dissolved. At the end the solution was centrifuged at 5000xg for 15 
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minutes in order to remove solid lumps. Then 2.5% DABCO (1.4-diazobicyclo-(2,2,2)-octane) 
were added.  Aliquotes of 1ml were stored at -20°C until usage.  
 
 
4.2. Immunohistochemistry:  
 
4.2.1. Mounting:  
 
Not dehydrated slides were mounted with vectashield (commercial fluorescent mounting 
solutionfor; Distrene-80- plasticizer- xylene)  and stored at 4°C. Glass cover was removed by 
leaving the slide in PBS for some minutes for doing an additional immunological stain.  
For mounting with moviol or DPX dehydration was performed using a rising alcohol series 
ending with xylol. 
 
4.2.2. Fluorescent labelling 
 
Slides were edged with an ImmunoPen (Calbiochem cat. no: 402176) for preventing the 
applicated liquid to float away. Then they were washed twice with PBS for 10 minutes.  A 
blockage of 10% serum according to  the secondary antibody, 0,25% Triton in PBS is applied 
for one hour. The incubation in the primary antibody diluted in 1% serum and 0.25% Triton in 
working solution was left  over night (o/n) at +4°C. 
This was followed by 3 washing steps using working solution. Afterwards the sections were 
incubated in the secondary antibody (see table 1 for references) at RT (room temperature) 
for one and a half hour. This was followed by two washes with working solution each 10 
minutes. Finally the sections were washed once with distilled water for getting rid of salts. 
 
4.2.3. 3,3'-Diaminobenzidine (DAB) labelling  
 
Slides were washed twice with PBS for 10 minutes. Then the endogenous peroxidase was 
inhibited for 30 minutes in H2O2 3%, MetOH 10% in PBS. The sections were washed 3 times 
for 10 minutes again. Then the sections were blocked for one hour in 10% serum, 0.25% 
triton in PBS for one hour. The primary antibody was incubated in working solution o/n. The 
slides were washed again 3 times in working solution before incubating them in the 
secondary antibody, which is coupled to biotin, diluted in PBST for one and a half hour.  
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During this incubation time the Vectastain ABC solution (cat. no PK6100), which contains 
hydrogen peroxide coupled to avidine,  was prepared mixing 1 drop of solution A with 1 drop 
of solution B in 5ml of 0.25% triton and storing this mix for 30 min before usage.  
The slides were washed again 3 times in working solution and were then incubated in the 
ABC mix for one hour, allowing avidine to stick to biotine. Afterwards the sections had to be 
washed once in working solution and twice in PBS. For detection 10ml of PBS were mixed 
with 5 mg DAB and 4µl of H2O2 (30%) (beneath laminar flow). Diaminobenzidine is oxidized 
by hydrogen peroxide to give a dark brown color. 
To stop the reaction the mix was washed off by PBS. The slides have been dehydrated by 
exposing them to an accelerating alcohol chain (60% - 80% - 90% - 100%) finally exposing 
them to xylol and mounting them immediately with DPX.  
 
4.2.4. Nissl Stain (cresil violet) 
 
The slides were exposed to the following solutions:  
Alcohol 100% for five minutes, alcohol 95% for  5 minutes, distilled water for two minutes, 
cresil violet for 10 minutes, distilled water for five minutes, alcohol 70%  twice two minutes, 
differentiation solution for one minute or less, dip into alcohol 95% three to five times, alcohol 
100% twice for two minutes and finally xylol . The slides were mounted with DPX 
immediately without drying out.  
Cresil violet solution preperation:  
2.5g of cresil violet acetate were disolved in 100ml of distilled water and afterwards filtered.  
 
4.3. Immunocytochemistry 
 
Cells were grown on coated dishes or on coated coverslips, depending on the cell type.  
Fixed cells were washed three times with PBS and could be stored in PBS at 4°C. Unspecific 
binding sites were blocked with blocking solution for 1 h at room temperature. 
Cells were incubated o/n with primary antibodies, diluted in working solution. Prior to 
incubation with the secondary antibody cells had been washed 
3 times with working solution for 10 min. Cells were incubated with fluorescence-labelled 
secondary antibody, diluted in working solution, for 2 h at room temperature in darkness. 
Cells have been washed three times with PBS for 10 min and rinsed immediately 
with ddH2O before they were mounted with moviol. 
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In case of antibodies directed against membrane proteins neither blocking solution nor 
working solution contained any detergent. 
4.3.1. Hoechst staining: 
 
1µl of Hoechst stock (1mg/ml) was diluted in 5000µl PBS 1 and cells were incubated in this 
solution for 10 min. After washing once with PBS the crystal slides were mounted with 
moviol. In case of using no crystal glasses the wells were stored with PBS at 4°C.  
 
 
 
4.4. Cytochemistry:  
 
4.4.1. Alkaline Phosphatase (AP) Detection Kit (Millipore, cat no. SCR004): 
 
Material: Fast Red Violet solution (o.8g/L stock), Naphthol AS-BI phosphate solution (4 
mg/ml) in  2-amino-methyl-1,3-propanediol (AMPD)  buffer (2mol/L), pH 9.5 
 
Staining Protocol:  
ES cells have  been cultured for one day prior to analyzing AP activity, at low to medium 
density. 
On day one, media was aspirated and ES cells were fixed with a fixative (e.g. 4% 
paraformaldehyde in PBS) for 1-2 minutes (Note: overfixation longer than 2 minutes results 
in the inactivation of AP). 
Fixative was aspirated and rinsed with 1x rinse Buffer. Wells must not dry.  
Reagents for AP staining are prepared (FVR:naphtol:water 2:1:1 ratio) 
0.5 ml of stain solution was added to each 24-well plate and incubated in dark at RT for 15 
minutes.  
Staining solution is aspirated and wells were rinsed with 1x rinse buffer. Cells were covered 
with PBS to prevent drying and photos of colonies expressing AP (red stem cell colonies) 
and differentiated colonies (colorless) were taken.  
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I. Table 1: Applied Antibody concentrations and commercial references 
 
primary 
antibodies Reference 
single 
IHH 
double 
IHH DAB ICC Host 
Aralar Housemade 1/100 1/100   1/100 Rabbit 
β-tubulin III Sigma T2200 1/250       Rabbit 
β-tubulin III Sigma T28660 1/300 1/500   1/2000 Mouse 
Caspase 3         1/200 Rabbit 
En1 Santa Cruz SC-8110   1/50   1/25     Goat 
Foxa 2 SC-7554 1/100 1/100 1/200   Goat 
GFAP Sigma Clone GA5 G3893       1/300 Mouse 
Ki67 RS RM-9106-S1 1/300 1/300   1/300 Mouse 
Nestin Abcam ab5968         Rabbit 
Nestin 
BD Transduction laboratories 
N17220-150 1/500       Mouse 
Neurogenin 2 Santa Cruz SC-1923 1/100   1/50 1/100   Goat 
Nurr1 Santa cruz SC-5568   1/50   1/200   Rabbit 
Oct4 Santa Cruz Biotechnolgy A1509       1/300 Rabbit 
Sox 2 Millipore AB5603 1/300     1/300 Rabbit 
SSEA1 Development Hibridome bank       1/50 Mouse 
TH mAb Millipore mAB 318 1/100 1/100   1/100 Mouse  
TH pAb Chemicon AB152 1/100 1/100   1/500 Rabbit 
TH pAb Pel-Freeze P40101-0 1/100 1/100    1/500 Rabbit 
TRp Hyd 
(serotonin) Sigma T8575       1/500 Goat 
secondary 
antibodies 
  
  
Alexa 555 α 
mouse Molecular Probes 1/300 1/300 1/300 1/300 Donkey 
Alexa 488 α 
rabbit Molecular Probes  1/300 1/300 1/300 1/300 chicken 
Alexa 488 α 
rabbit Molecular Probes 1/300 1/300 1/300 1/300 Goat 
Alexa 555 α 
goat Molecular Probes  1/300 1/300 1/300 1/300 Donkey 
BA 1000 α 
rabbit Vector     1/200   Goat 
 
4.5. Cell culture methods:  
 
4.5.1. Preperation of culture dishes 
 
Using Polylysine:  
The culture dishes were covered with polylysine (10μg/ml) and incubated for at least one 
hour (or o/n) at 37° C. Then they are washed three times with PBS.   
If crystal slides were used the polylysine was applied at a higher concentration 25-30μg/ml.  
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Using polylysine and laminin:  
With polylysine pretreated culture dishes were covered with laminin (1μg/ml of 1000x) and 
incubated o/n.  
 
Using gelatin: 
Gelatin 0.1% in PBS was used to treat dishes for cultivation of embryonic stem cells or 
feeder cells and 0.2% gelatin for cultivation of cells on crystal slides. 
 
4.5.2. Passaging of cells:  
 
All media and used components (Trypsin /EDTA, PBS/ EDTA, gelatin, media) were 
assimilated to room temperature. The old medium was drawn off the culture dishes. The cells 
were washed with PBS/EDTA for 3-4 min. For trypsinizing a certain amount of trypsin was 
added depending on the size of culture dish and cultured for 5 minutes until all cells have 
deattached from the culture dish.  
 P6 P12 P24 P35 P60 P100 Flask 600 
Μl 200 100 50 250 400 1000 2000 
   
For stopping the reaction 1 ml medium was added. The mixture was transferred to a falcon 
tube and centrifuged for 5 min at 1000 rpm. The medium was carefully drawn off and cells 
were resuspended in 1ml of medium.  
For counting 10μl of trypan blue and 1μl of cells were mixed. 10μl were then pipetted into a 
Neubauer counting chamber and an area consisting of 16 smaller quadratic panels was 
counted. The desired solution was calculated so that the right amount of medium could be 
added to the cells. In the end the medium containing the resuspended cells was distributed 
to the new previously gelatinized dishes.  
 
4.5.3. Mitotical inactivation 
 
Once feeder cells (MEFs or stromal PA6 cells) of a dish had almost reached total confluency 
(~90%) they were treated with mitomycin C. This procedure keeps the cells in a non 
proliferative state.  
The medium was drawn off the culture dish. 10μl mitomycin C (1mg/ml)/10ml of cell 
according medium (endconcentration: 10µg/ml )were applied for 2 up to 4 hours. 
Alternatively 1μl mitomycin C (1mg/ml)/ 1ml of medium was applied o/n (10ml/ p100).  
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4.5.4. Freezing of Cells 
 
The medium was taken off. Cells were washed with PBS EDTA. One ml of trypsin was added 
to a p100 dish and incubated for 5 minutes at 37°C. The reaction was stopped by adding 1ml 
of medium. Then cells were easily removable from the dish for centrifugation in 20ml of 
medium for 5 minutes at 1000 rpm. The supernatant was taken off and the pellet was 
resuspended in freezing medium (10% DMSO in normal medium for MEF or PA6 or mES). 
Cells were kept at -80°C after at least 24 h stored in liquid nitrogen.  
 
4.5.5. Thawing of Cells  
 
Frozen cells were smoothly rotated in the water bath before resuspending in 1ml of medium. 
Then the resuspended cells were mixed with another 9ml of medium for centrifugation at 
1000 rpm for 5 minutes.  The supernatant was taken off and the cell pellet was resuspended 
in 1ml of medium.  
According to the desired concentration a certain amount of resuspended cells was distributed 
equally on a pretreated culture dish. The dishes were moved smoothly from east to west and 
from north to south, thereby preventing cells from accumulation in the center and growing 
radially outwards, which would have lead to cell death in the center, poor cell harvest at the 
edges.   
 
4.5.6. Derivation of dopaminergic neuronal precursors of the ventral 
mesencephalon 
 
Culture dishes (24 or 48 wells) coated with only poly-lysine and dishes coated with poly-lys + 
laminine (1µg/ml) have been prepared in advance.  
One box with ice was prepared. The embryonic age 13.5 (E13.5) embryos were extracted 
from the uterus of the female and put directly into cool PBS. The horns were put into a 100-
mm-diameter culture dish with 20ml of PBS. A culture hood equipped with a dissection scope 
and dissection forceps and scissors that have been autoclaved (or cleaned and submerged 
in 70% ethanol) were used. The embryos and placenta from the uterine horns were released 
by cutting the walls of the horn and then each embryo was separated from the placenta and 
surrounding membranes. The heads were cut off. The ventral mesencephalon was dissected 
and cut into small pieces, which were put in PBS with glucose (5% autoclaved). Once all 
embryos have been processed the pieces were all choped by pipetting them in pasteur 
pipets of different diameters. 
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A little bit of medium was added. The tissue was centrifuged 5 minutes at 400 rpm.  
The pellet was resuspended in 1-2ml of medium and cells were counted. The cells were 
seeded at approx. 75-100.000 cells per well (if p24 were used). In case of polylysine and 
laminine coated culture dishes a drop of cell suspension was applied and left 5 minutes for 
adhesion. Then more medium was added (for p48 a drop of 10µl was applied containing 
40000 cells and later on 150µl of medium is added, for p4 a drop of 20µl was applied 
containing 80-10000 cells and 200-300µl of medium was added). 
In case of single embryo cultures cells of each embryo were counted, therefore cells had to 
be resuspended in very little medium (at the most 100µl) after centrifugation. Usually one 
embryo midbrain contained around 200000 cells. In case of polylysine all the cells were first 
resuspended in their final volume and then equally distributed to the wells.  The cells were 
cultured at low oxygen tension for obtaining better results.  
 
 
4.5.7. Derivation of mouse embryonic stem cells: [44] 
 
Derivation of mouse embryonic fibroblasts (MEFs) 
100mm tissue culture plates were prepared and labelled. Usually the MEFs from two 
embryos provide a sufficient number of cells for one plate.  
A pregnant female mouse between 12.5 and 13.5 days post coitum was sacrifyed. The 
uterine horns with the embryos were dissected out and put into a 100-mm-diameter culture 
dish with 20ml of cold PBS. A culture hood equipped with a dissection scope and dissection 
forceps and scissors that had been autoclaved (or cleaned and submerged in 70% ethanol) 
were used. The embryos and placenta from the uterine horns were released by cutting the 
walls of the horn and then each embryo was separated from the placenta and surrounding 
membranes.  
The heads were cut out and all the internal abdominal and thoracic organs (lungs, heart, 
liver, intestine, stomach, etc.) were removed from all embryos in a litter. The embryonal 
tissue was trypsinized by transferring all embryos to 35-mm-diameter dishes with 1ml of 
0.25%  trypsin/EDTA (two embryos per plate). The tissue was trypsinized 15 min in a 37°C 
incubator or water bath until tissues started to disintegrate. The tissue was pipetted up and 
down quickly with a 1ml pipette to achieve efficient dissociation. In case when more than ten 
embryos were obtained, the extra embryos were kept in ice-cold PBS for up to 15 min 
without affecting MEF viability. To short incubation may result in insufficient trypsinization 
and low yield, whereas too prolonged incubation may decrease the viability of MEFs. 
Needles and syringes have to be avoided for dissociation.   
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The cell suspension in trypsin was inactivated by pipetting it into the MEF culture medium 
(1ml of suspension per 10ml of medium). The embryos from one female were pooled in one 
50ml tube (or in two 50-tubes when more than ten embryos are obtained). The large pieces 
of tissue sedimented. The supernatant was collected and seeded out as a homogenous 
suspension, keeping a ratio of two embryos per 100-mm plate.  
The culture medium had to be changed 4-5 h after seeding to remove unattached cells. The 
MEFs were grown until 90% confluence (it usually takes 2-3 days). MEFs at this stage ready 
to be frozen were considered to be passage 1. The MEFs can be frozen for several weeks at 
-80°C or for unlimited time in liquid nitrogen.  
If MEFs were going to be frozen down, cells from one 100-mm plate were frozen per single 
vial using standard cell culture techniques. When using frozen MEFs, the cells were usually 
ready for mytomycin treatment one day after thawing (if thawed, 1 vial per 100-mm dish). 
Alternatively, when thawed MEFs were confluent, they were split 1:3 to generate three plates 
of passage 2 MEFs. 
 
Preparation of MEF feeder layer : 
12-well, 24-well or 6cm plates were gelatinized by covering the bottom of wells with 0.1% 
gelatin for a minimum of 5 min at 37°C. The gelatin solution was removed just before next 
step.  After mitomycin C inactivation, MEFs were washed once with 
PBS, trypsinized, counted and seeded at a density of 20,000–25,000 cells per cm2 onto 
gelatinized wells. The feeder layer covered the entire well. Wells in which the MEF feeder 
layer was not confluent have not been used.  
 
Blastocyst extraction and ICM expansion  
MEF medium was replaced with SR-ES medium 1–3 h before blastocysts extraction. Only 
freshly prepared MEF feeder layers were used (prepared the same or previous day) to avoid 
the retraction/detachment of feeder and in order to preserve feeder properties, which could 
negatively influence ESC derivation. Time-mated females at E3.5 were killed and 
immediately dissected putting their uteri into 10ml of HEPES/DMEM in 100-mm plate 
preheated to 37°C in the incubator. The uteri were transferred into 2ml of fresh preheated 
HEPES/DMEM in 35-mm dish or as an alternative into an organ tissue culture dish (more 
expensive but more convenient). The blastocysts were flushed out of the uterine horn under 
a dissection scope using a 1-ml syringe with 23-G needle. Then they were collected under an 
inverted microscope using 10ml pipette tips and a 20-ml pipette and transferred individually 
to wells of a 12-well plate containing a feeder layer of MEFs mitotically inactivated 1 d earlier. 
Blastocysts are not readily visible in dissection microscope. Using an inverted microscope 
with phase contrast made identification much easier. Blastocysts attachment to the MEF 
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feeder layer usually took 2 days. Any interference during this period has been avoided. After 
attachment, the blastocysts hatched. SR-ES medium has then been changed, and was 
subsequently replaced every second day while the inner cell mass expanded, until adopting 
a different morphology (usually on day 5 or 6). The plate has not been shaked or moved 
during attachment. 
 
First trypsinization and ESC expansion 
Appropriate numbers of 12-well plates with confluent layers of mitotically inactivated MEFs 
were prepared and labelled 1 day in advance. Two hours before trypsinization,  the MEF 
medium was replaced with 1 ml per well of FBS-ES medium.  20-µl drops of 2.5% trypsin 
were made on a 60-mm-diameter culture dish. SR-ES medium was aspirated from the wells 
containing expanded blastocysts on MEFs and 200 ml of 0.25% trypsin-EDTA was added to 
the well. After 15 s, the trypsin-EDTA was aspirated, leaving only a wet surface. This 
procedure reduced stickiness of the cells and allows easier detachment.  To mechanically 
detach an expanded blastocyst and surrounding MEFs, a 20-ml pipette and 10-ml pipette tip 
were used. Under a dissection microscope, 10µl of 2.5% trypsin from the 20-µl drops were 
pipetted onto each blastocyst (one at the time). Several circles were made with the pipette tip 
around the blastocyst to remove surrounding MEFs and separate the blastocyst (on the top 
of some MEFs) from the rest of the feeder layer. The blastocyst was aspirated back with the 
pipette and transferred into the remaining 10-µl drop of 2.5% trypsin. 
 MEFs cultured in SR-ES medium for 5–6 days produce large amounts of extracellular matrix 
resistant to trypsin, which increases their stickiness. To make sure that the blastocyst was 
successfully transferred it was checked for its presence under the dissection microscope. 
The cells were trypsinized in a drop for 5 min in the 37°C incubator and then dissociated into 
individual cells and small cell clumps, by pipetting up and down approximately ten times with 
a 10-ml pipette tip. Dissociation was monitored under the dissection microscope until the 
blastocyst was disintegrated into several smaller cell clumps. The cell suspension was 
pipetted into a well of a 12-well plate containing MEFs and FBS-ES medium. The next day, 
FBS-ES medium was replaced with SR-ES medium and the cells were let continue growing, 
changing the medium every second day. Several days after trypsinization, compact cell 
colonies with typical ESC colony morphology were detected in some of the wells (the number 
of colonies usually varied from 1 to 20). The colonies were monitored daily, focusing 
especially on colony morphology and growth. 
ESCs were passaged according to their needs. All cells were trypsinized in a well with 0.25% 
trypsin-EDTA when most colonies in the well reached a certain morphology. The resulting 
single-cell suspension was mixed with FBS-ES medium and the cells were seeded in a dish 
(well) of suitable size containing fresh feeder cells. The next day, the medium was replaced 
with SR-ES medium. Usually an additional trypsinization step was needed before the cells 
were grown on 60-mm-diameter dishes to sub-confluency before being frozen. 
 
5) Figure 5. Scheme of extraction protocol  47 
 
4.5.8. Feeder layers for mES cells: 
 
P 6cm diameter 800000 or at least 600 000 cells 
P6 6 wells/plate 400000 or at least 300 000 cells  
P4  4 wells/plate  80000 or at least 60 000 cells 
P24 24 wells/plate 80000 or at least 60000 cells 
P12 12 wells/plate 200000 
PA6 were used for mES cell differentiation 
MEFs were used for mES cell proliferation, blastocyte derivation (confluency and freshness, 
low passage ≤3 very important). 
 
4.5.9. mES cell peculiarities: 
 
Changing the medium, cells have been washed once with SRM. When trypsinized the 0,5% 
trypsin (+EDTA 0,2%) was applied. Cells had to be disintegrated pipetting them quite a few 
times with p1000 or p200 pipetts up and down. Too much disintegration before freezing cells 
down resulted in poorer cell survival. The centrifugation was performed at a maximum speed 
of 1000 rpm for 5 minutes. 
 
4.5.10. Neomycine (G418) selection 
 
Cells were seeded in SR-ES containing LIF and 500µg/ml G418 or 250 µg/ml G418 
respectively. Growing cells have been monitored after 4 and 8 days and examined on cell 
mortality. Phase contrast images have been taken.  
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4.5.11. Differentiation of mouse embryonic stem cells towards dopaminergic 
fate (adjusted from Barberi et al. 2003 [11]) 
mES cells were trypsinized and replated at single-cell densities (depending on how many 
MEF cells they contained) on gelatine coated dishes containing a confluent PA6 cell layer 
prepared the previous day in SRM medium without LIF.  Factors have been preresuspended 
in HSC 2000 medium. After 5 days of culture, 200ng/ml SHH and 25ng/ml FGF8 were added 
to the SRM for patterning, and then the medium was changed to N2 supplemented with SHH 
and FGF8 in the presence of 10ng/ml bFGF (days 8−11). At day 11, terminal differentiation 
was induced by withdrawal of SHH, FGF8 and bFGF and the addition of 200µM ascorbic 
acid, 20ng/ml GDNF and 10ng/ml BDNF.  
If mES had already grown on gelatin for several passages 150 cells/well of p4 or p24 were 
seeded, if mES had so far been grown on a confluent MEF layer 200 cells/well of p4 were 
seeded, as cell countings included MEF cells. 
 
4.5.12. Collection of cells for DNA extraction 
 
Cells were washed twice with PBS before beeing trypsinized for 5 minutes. Afterwards 200µl 
of medium were added, the 15 ml tube was filled up with PBS for stopping trypsinization and 
cells (also mES) were centrifuged at 1000 rpm for 5 min. Supernatant was taken of. Pellet 
can be stored at - 20°C or resuspended in PBS. 
 
4.5.13. Cell lysis for Western blot analysis 
 
Cells were washed twice with cold PBS and put on ice immediately. 100µl of lysis buffer were 
added to P6 wells. Cells were scraped of the wells using cell scrubber and transferred into a 
1.5ml eppendorf on ice. Then they were homogenized by sonication. Proteins either were 
used immediately or were stored at -20°C until their usage.  
 
Lysis buffer:  pH 7.5 
Hepes  50mM 
NaCl   150 mM 
MgCl2  1mM 
CaCl2  1 mM 
Na4P2O7 10mM 
NaF  10mM 
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EDTA  2mM 
Glycerol 10% 
Np-40  1% 
added just before usage: 
1 inhibitor mix tablet Roche (ref.: 11836170001) in 10 ml lysis buffer.   
 
4.5.14. Determination of protein concentration using Bradford assay 
 
Reference curve: 1-50 µg/ml BSA 
BSA (µl) H2O (µl) Bradford 
0 800 200µl 
1 799 200µl 
5 795 200µl 
10 790 200µl 
20 780 200µl 
50 750 200µl 
 
Stock BSA: 1mg/ml 
After adding Bradford reagent samples were incubated between 5 minutes and one hour.  
Measurements were done at OD 595 nm. Linear zone of graph was chosen as a reference.  
 
4.5.15. Media, solutions and equipment for cell culture  
 
- Mouse stromal cell medium (PA6 cell line) 
- αMEM (Gibco, ref: 32571-028) 
- 10% FBS (bibco, ref: 10270-106) 
- 1% L-Glutamine 
- PA6 freezing medium 
- 80% PA6 medium 
- 10% FBS 
- 10% DMSO 
- Mitomycin C (Roche) 
- 10µg/ml (stock 1mg/ml), medium (PA6 or MEF) 
- sterile and cool PBS with glucose (stock: 10% ) 
- N2 medium + non essential amino acids with and without B27 (1%) 
- sterile Petri dishes for dissection 
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- 12 (Falcon, multiwell 12-well, cat. no. 353043), 24, 48 well, 35-, 60- and 100-mm tissue 
culture plates 
- 2.5% (Gibco, cat. no. 15090-046), 0.25%  trypsin (Gibco, cat. no. 25300-54) 
- MEF culture medium: D-MEM supplemented with 10% FBS (Gibco, cat. no. 10270-106), 
penicillin (100 U ml–1)/streptomycin (100 mg ml–1) (Gibco, cat. no. 15140-122) and 2 mM L-
glutamine (Gibco, cat. no. 25030-024)  
If DMEM had been opened several weeks before use 1ml /100ml of glutamine was added. 
- MEF freezing medium (MEF culture medium + 10% FBS (increases survival rate) + 10% 
DMSO) 
- Dissection scope 
- 10ml pipette tips (Gilson, Diamond D10, cat. no. F161632; Sarstedt, cat. no. 
70.1130; or similar) 
- 20ml pipette 
- Dissection forceps and scissors 
- PBS, without calcium or magnesium 
- 70% (v/v) ethanol 
- E12.5 or E13.5 mouse embryos 
- 0.1% gelatin: 1 g of gelatin was disolved (Sigma, cat. no. G1890) in PBS 1x and sterilized 
by autoclaving 30 min at 120 °C 
- HEPES/DMEM 
-     7.5ml Hepes 1M (100x, Gibco, cat. no. 15630-056) 
- 500ml Knock out (KO) DMEM (Gibco, cat. no. 10829-018) 
- FBS-ES medium, a medium similar to SR-ES medium, in which SR was replaced by 20% 
ES cell-pretested FBS (PAA, cat. no. A15-080) 
- 23-G needles (0.6 x 25 mm) 
- 1-ml syringes 
- Inverted microscope with phase contrast 
- SR-ES medium (500ml) 
- 390ml KO DMEM  (Gibco, cat. no. 10829-018) (light sensitive) in case of derivation, 
usually: 415ml.  
- 100ml (20%) KO serum replacement (SR) (Gibco, cat. no. 10828-028) in case of 
derivation, usually: 75ml (10%) KO SR  
- 5ml 200 mM L-Glutamine (Gibco, cat. no. 25030-024) 
- 500µl 1:1000 non-essential aminoacids 
- 5ml 10000 U/ml pen/strep  (1:1000) 
- 500µl  1000 U/ml LIF (ESGRO, Chemicon) (1 µl/ml) 
- 1ml 0,1mM β-ME (stock: 88 µl  β-ME in 25 ml PBS) (2 µl/ml) 
 
 
36
For passaging or handling a LIF-free version of the medium was used.   
- mES freezing medium 
- 90 % FBS (Gibco, cat. no. 10270-106) 
- 10% DMSO (Sigma cat. no, D2650) 
- HSC 2002 
- DMEM/F12 (1:1) with Glutamax I, Liquid, 1x, Gibco cat. no: 31331-028. stored at 
4°C) 
- glucose 30% (Sigma cat. no. G7021) DMEM/F12 was dissolved at 30% (w:v), 
filtered, aliquoted and frozen) 
- 1M HEPEs (Gibco cat. No. 15630-056) aliquoted and stored at 4°C 
- AlbuMAX-I (Gibco cat. no.  17502-048) 3mg/ml 
- N2 medium 
 - HSC 2002 
 - N2 supplements 100x (Gibco cat. no. 17502-048) aliquoted and frozen 
 - Non essential AA 100x (home made) Aliquoted and frozen 
 - Pen/strep 1000x mix (home made) aliquoted and frozen 
- PBS EDTA (0.02%): 50ml EDTA (0.2%, stock)  
       450ml PBS 
 
4.5.16. Fixatives and other solutions:  
 
- PSP 0.1M 
  - 25ml PFA 16% 
- 50ml PHEM 2x 
- 20ml saccharose 0.6M 
- 2.5ml H2O 
- 2.5ml PB 0.2M 
- PFA 16%: Dissolved in 50% H2O and 50% PB 0.2M while heated to 50°C. 
pH was adjusted to 7.4 using NaOH. 
Filter through filter paper. Storage at -20°C is possible otherwise it is stored at 4°C. 
- PHEM 2x  
-120mM PIPES   
- 50mM HEPES  
- 20mM EGTA 
- 4mM MgCl2 
  dissolved in 50% H2O and 50% PB 0.2M –  pH was adjusted to 6.9 
- Saccharose 0.6 M in 50% H2O and 50% PB 0.2M 
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4.6. Animal treatment:  
 
Aralar deficient animals were a kind gift of the laboratory of Prof. Jorgina Satrústegui: 
These animals have been developed and published first by Jalil et al. [1].  
slc25a12+/- (Aralar+/-) mice were housed with a 12-h light cycle and fed ad libitum on 
standard chow. Animals were sacrificed by cervical dislocation. All animal procedures were 
approved by European guidelines and guidelines of the Universidad Autonoma de Madrid 
(UAM).  
 
4.6.1. Animal mating:  
 
As aralar knock out mice are not viable enough time for being fertile aralar (+/-) females were 
mated with aralar (+/-) males for obtaining aralar (-/-) embryos and also (+/+) littermates of 
exactly the same age. The genotype of each embryo and also of the embryo derived primary 
cultures and ESC cultures was determined individually. Detection of vaginal plug was 
considered as embrionic day 0.5 (E0.5) postconception. At least three different embryos 
were used for each immunohistochemical staining.  
 
Embryos or fetuses were removed from the uterus and their crown-rump length (CRL) was 
recorded. Specimens of the following average CRLs were selected: E11.5: 7-8mm, E13.5: 9 
mm, E15.5: 16,13 mm. 
 
4.6.2. Fixation and cutting of mouse brains and mouse embryos for 
immunohistochemistry: 
 
After dissection of the embryo it can be stored for some minutes in cold PBS.  
Then the embryos were transferred to paraformaldehyde 4% for two, four or 24 hours. 
Afterwards they were cryo-protected in firstly 20% and then 30% sucrose/PBS until the 
embryos were saturated and sank to the bottom of the tubes.  
The tissue was embedded in O.C.T™ Compound (Tissue-Tek cat. no: 4583) using self made 
peel away molds and stored at -70°C until sectioning.  Serial sections, in the sagittal planes, 
were cut at 14 µm on a cryostat.  From animals older than E13 only heads were embedded 
younger embryos were embedded, as a whole. Prior to sectioning the olfactory bulbs, 
coronal sections were first oriented according to the nasal passages. Left-right and dorsal-
ventral orientation were adjusted as needed. Final adjustments to the orientation were made 
in the region of the striatum. Then the orientation was maintained for the remaining sections. 
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The serial sections were thaw-mounted onto Menzel Superfrost Ultra Plus Microscope slides 
in sets of 8 upto 12 slides. Once the sections had dried onto the slides they were 
immediately stored in a slide box at -70°C until they were stained.  
 
 
4.7. Genotyping:  
 
4.7.1. Isolation of Nucleic acids from cultured cells (High pure PCR Template 
Preperation Kit, Roche, cat. no: 11796828001)  
 
Adjustment of sample volume:  
Medium with 104 - 106 cultured mammalian cells were centrifuged and the pellet was 
resuspended in 200µl PBS.  
  
Sample lysis and DNA Binding:  
To a nuclease free 1,5ml microcentrifuge tube 200µl of sample material, 20 µl of binding 
buffer, 40µl of proteinase K (reconstituted) were added, mixed immediately and incubated at 
70°C for 10 min. Then 100µl of isopropanol were added and the well was mixed. 
After inserting one High Filter Tube in one Collection Tube the sample was pipetted into the 
upper buffer reservoir of the filter Tube. The High Pure Filter Tube assembly was inserted 
into a standard table top centrifuge and centrifuged for 1 minute at 8,000 x g.  
Afterwards sample was proceeded as described in Washing and Elution below. 
  
4.7.2. Isolation of Nucleic Acids form mammalian tissue  
 
Sample lysis and DNA binding:  
25-50mg of tissue were used. Before starting the purification reaction, the Elution Buffer was 
warmed up to 70° C. To a nuclease-free 1,5ml micro centrifuge tube 25-50mg of sample 
material was added. Then 200µl Tissue Lysis buffer and 40µl proteinase K (reconstituted) 
were added and mixed immediately. This mixture was incubated for one hour at 55°C or until 
tissue was digested completely. The yield of nucleic acids was increased by cutting the 
sample with a scalpel in small pieces before incubation. 200µl binding buffer were added and 
mixed immediately. The mixture was incubated for ten minutes at 70°C. 100µl isopropanol 
(2-Propanol) was added and mixed well. Insoluble tissue segments were drawn out of the 
sample into a 1ml disposable pipette tipp. One High Filter Tube was inserted in one 
collection tube. The remaining liquid sample was pipeted into the upper buffer reservoir of 
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the Filter tube. The entire High Pure Filter Tube assembly was inserted into a standard table-
top centrifuge and centrifuged for one minute at 92000 rpm (8,000 x g).  
 
Washing and Elution:  
The Filter Tube was removed from the collection tube and the flow through liquid in the 
Collection Tube was discarded.  The Filter Tube was combined with a new Collection Tube. 
500µl Inhibitor Removal buffer rare added to the upper reservoir of the Filter Tube and 
centrifuged for one minute at 92000 rpm. The Filter tube was then removed from the 
Collection Tube and combined with a new Collection Tube. 500µl washing Buffer was added 
to the upper reservoir of the Filter Tube and centrifuged for one minute at 92000 rpm. The 
Filter tube was then removed again from the Collection Tube and combined it with a new 
Collection Tube. 500µl washing Buffer was added to the upper reservoir of the Filter Tube 
and centrifuged for one minute at 92000 rpm. After discarding the flow through liquid the 
High Pure asambly was centrifuged for additional ten seconds at full speed before discarting 
the Collection Tube which ensured removal of residual Wash Buffer. To elute the DNA the 
Filter Tube was inserted into a clean, sterile 1,5ml micro centrifuge tube and 200µl 
prewarmed Elution buffer was added to the upper reservoir of the Filter Tube and centrifuged 
for five minutes at 92000 rpm.  
By then the micro centrifuge tube contained the eluted DNA. The eluted DNA was either 
used immediately or stored at +2 to +8° C or at -25°C for later analysis.  
 
4.7.3. Evaluation of quantity and quality of extracted DNA using Nanodrop-1000 
UV/Vis-spectral photometer:  
 
For making sure that the extracted samples contained enough DNA and were not 
contaminated by proteins spectralphotometry was used. After inserting a blank, in this case 
elution buffer of the extraction kit, 1µl of sample was inserted and measured for A 260 and 
A280. One D260 value corresponds 50µg of DNA, therefore the constant used by the 
program was 50. 260/280 ratios in the range of 1.8 to 2 were accepted regarding protein 
contamination. For PCR reactions quantities in the range of 100ng to 500ng were used: 
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4.7.4. PCR:  
 
Used primers:   
INT 13B: 5´-ACCACCACCAGCGTGTCAGC-3´ 
LTR: 5`-GTTCTCTAGAAACTGCTCAGG-3` 
INT 13Fi: GATGTGAGAACTCACCAGTGT-3` 
13Fi and 13B: produce wildtype (271 bp) 
LTRF3 and 13B: produce knock out ( 406 bp) 
 
dNTPs: dATP, dCTP, dGTP, dTTP (10mM) 
100mM stocks are stored and diluted to 10mM.  
 
Mixture of Oligos: LTRF3:13B:13Fi ?1:1:0.5 
 
PCR Program:  
- initial denaturation  5 min 94°C 
- Cycles 30x:    1 min 94°C 
    30 sec 58 °C 
    30 sec 72°C 
- final extension:   5 min 72°C 
 
Mastermix:      Final concentration 
Buffer 10x 2.5µl   
 Mix Oligos 2µl   
 MgCl2  1µl   2mM  
 dNTPs 0.5µl (10mM) 2mM 
 dH2O  12µl 
 Total:  18µl 
 
Mix:    18µl Mastermix 
   5µl DNA 
   2µl Polymerase (Biotools 50mM 1:3 in dH2O) 
  Total:  25µl 
 
One negative control consisting of distilled water instead of DNA and positive controls for 
WT, KO and HET were always included. 
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4.7.5. Gel electrophoresis:  
 
A 1,5% Agarose gel was prepared with TAE (150ml + 4µl Ethidium Bromide).  Samples were 
mixed with loading dye (bromphenolblue). 20µl of sample were loaded. As a marker 2 µl of ϕ 
29 DNA/Hind III (500ng/µl) (housemade) were  used. 
The electrophoresis was run at 100 V for approx. 50min.  
 
Loading dye:  
0.25% Bromophenol blue 
40% saccharose  
TAE 50x (1L): 
242g TRIS 
57ml cold acetic acid 
100ml EDTA 0.5M 
ad 1000ml H2O  
 
4.8. SDS Page and Western Blot 
 
4.8.1. SDS PAGE 
 
Gels were usually prepared one day before usage and stored at 4°C in a humide chamber 
for better polymerization. Before gel preparation gel boxes were cleaned and the according 
glass slides were inserted and fixed diagonally. Afterwards the boxes were confirmed to be 
leak proof and indications at the depth of the slot comb were drawn.  
Gels were prepared according to the molecular weight of the proteins that were going to be 
detected. In case of aralar which has 74 kDA 10% gels were prepared.  
The separation gels were prepared as follows in chronological order adding the radical 
starters for polymerisation in the end.   
 6% 8% 10% 12% 15% 
 1 Gel 2 Gels 1 Gel 2 Gels 1 Gel 2 Gels 1 Gel 2 Gels 1 Gel 2 Gels 
H2O mQ 2.75 5.5 2.5 5 2.25 4.5 2 4 1.75 3.5 
Acrylamide/Bisacryl
amide mix mix 40% 
0.75 1.5 1 2 1.25 2.5 1.5 3 1.87 3.75 
Tris-HCl 1.5M pH8.8 1.3 2.6 1.3 2.6 1.3 2.6 1.3 2.6 1.3 2.6 
SDS 10%  0.05 0.1 0.05 0.1 0.05 0.1 0.05 0.1 0.05 0.1 
APS 10% 0.05 0.1 0.05 0.1 0.05 0.1 0.05 0.1 0.05 0.1 
TEMED 0.005 0.01 0.01 0.01 0.005 0.01 0.01 0.01 0.01 0.01 
 
 
42
 
After filling in the first gel until approximately 1cm below the indication (approx. 4ml ) the gel 
was covered with isopropanol until it polymerized. After polymerization the isopropanol was 
taken off for filling in the stacking gel.  
The stacking gels were prepared as follows : 
Stacking gel: 4% 
 1 Gel 2 Gels 
H20 mQ 2.3 4,6 
Acrylamide/Bisacrylamide 
mix 40% 
0.3 0.6 
Tris-HCl 0.5M pH6.8 0.38 0.76 
SDS 10%  0.03 0.06 
APS 10% 0.03 0.06 
TEMED 0.005 0.01 
 
One liter of Tris-Glycin buffer was prepared.  
Desired amounts of samples and unstained molecular weight marker were mixed with 
laemmli buffer and denatured for 3-5 minutes at 100°C. 10 – 20µl of samples and 
Kaleidoscope Prestained Standards marker from BIO-RAD (cat. no: 161-0324) were loaded. 
Unused slots were filled with H2O+laemmli buffer. Buffer was added into the gel 
electrophoresis box. Electrophoresis was run at at 50 - 70 V until samples enter separation 
gel. Further on voltage was increased to 100 up to 200V. Electrophoresis was stopped when 
the dye front had started running off the bottom of the gel. 
 
Tris-HCl 1.5M (pH-8.8) 500 ml  
90.82g in 350ml dH2O  
Adjust pH 8.8 with HCl  
ad 500ml   
Tris-HCl 0.5M (pH-6.8) 500ml 
30.27g Tris in 350ml H20 
Adjust pH 6.8 with HCl  
ad 500ml  
SDS 10% 
25g SDS in 250ml H20 cover with aluminium paper and leave it o/n. 
10% APS  
A pinch of APS was weighted and as many µl of H2O as mg APS were added.  
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Laemmli buffer 2x  
2.5ml Tris-HCl pH 6.8 0.5M  
4ml SDS 10%  
0.3ml EDTA 0.5M pH8   
1ml β-mercaptoethanol 98%  
2. 29ml glycerol 
a little bit of bromophenol blue 20mg 
Electrophoresis buffer5X 1L 
15.12g Tris  
72.06g glycine 
5g SDS 
 
Acrylamide mix 
29.2 g acrylamide and 0.8 bisacrylamide were weighted on aluminium foil paper in a 250 ml 
flask using a spatula and a mouth cover. 50ml dH2O were added and left wrapped in 
aluminium paper shaking o/n. 
100ml dH2O milliQ were added then the solution was filtered. 
 
TBS 10x (1l) 
NaCl 1.5 M 87,66g 
Tris-HCL 0.1 M 12,15g 
Ad 1000ml dH2O adjust pH to 7.5 
 
Ponceau red 
0.2% Ponceau red in 3% acetic acid 
1g ponceau red in 7.5ml acetic acid 
 
4.8.2. Transfere using inmobilon-P filter 
 
Transfer buffer 
3.02g Tris 
14.42g glicine 
Disolve in 600ml dH2O  
ad 800ml dH2O  
at last 200ml pure metOH were added.  
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After finishing the electrophoresis, the gel was taken out, the stacking gel cut off and the 
separation gel rinsed in transfer buffer. One inmobilon-P filter was rinsed in 100% methanol 
for 15 seconds before incubating it in dH2O for two minutes and passing it for at least 5 
minutes to transfer buffer. The transfer cassette was mounted as follows from the positive 
pole side towards negative pole side (red):  
White sponge, filter paper, inmobilon-P filter, gel, filter paper, white sponge rinsing everything 
in transfer buffer avoiding bubbles. The sandwich and a block of ice were inserted into a 
BioRad Mini Protean tetra cell blotting box containing already a rotary magnet and the same 
was filled with transfer buffer covering the upper electrode. The box was located on a 
magnetic stirrer. The transfer is usually run at 100V, Amperase indicating ~300A for one 
hour. If Ampere value was above 500 transfer buffer was changed. After transfer the filter 
was stained in ponceau red solution during 1-2 minutes for a reversible stain of proteins. For 
destaining the filter was washed with dH20. The filter was activated in methanol for 10 
seconds and dried for 15 minutes between two filters before immunostaining or storage at –
20°C.  
 
4.8.3. Antibody incubation using Inmobilon- P filter 
 
Blocking solution:  
BSA 1% (or 5% milk) Tween20 0.05% in PBS.  
Filter was incubated with primary antibody (Aralar 1:1000) diluted at appropriate 
concentration in blocking solution for one hour at room temperature without prior blockage 
(5ml for one membrane). Primary antibody was reuptaken and could be stored for up to one 
week at -20°C. Membrane was washed twice in PBS before incubation with a horse radish 
peroxidase (hrp) coupled secondary antibody (GAR P/O goat α rabbit Nordic Immuno 
1:5000)  diluted in blocking solution for 30 minutes (5ml for one membrane). Membrane was 
washed again twice with PBS for 10 seconds and was then incubated in PBS Tween20 0.5% 
for permeabilisation until membrane looks transparent. 
For detection membranes were incubated with HRP substrate solution (Western Lightening 
Chemiluminescence Reagent, Perkin Elmer Las, cat. no: NEL102) for 5 min and exposed to 
film (AGFA). 
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4.8.4. Stripping for Western blot 
 
Sodium acid: Eliminates peroxidases of secondary antibodies.  
TBS + sodium acid 0.2% 
Membranes were washed in TBS for 10 minutes and incubated for 20 minutes at RT in 
stripping buffer. Afterwards they were washed twice in TBS for ten minutes at RT. For 
confirmation of signal elimination one revelation test with ECL reaction was done.  Before 
incubation with another antibody membrane was dried or a blocking step was added.  
4.9. Quantification and data analysis:  
 
Images were obtained by an inverted Leica DM IRB microscope capturing images by a Leica 
DC 100 camara operated by Adobe PhotoShop 5.0 (Pantone Inc) and a vertical Axioskop2 
plus microscope (Zeiss) coupled to a Coolsnap FX color camara navigated by Metavue 5.07 
(Universal Imaging). 
They have been processed in Adobe Photoshop CS3 extended and Image J.  
For area quantification relative values of expression area against croped areas of the same 
size were calculated.  
For cell quantification in stained tissue sections cell number per captured field was counted 
from various comparable sections of at least 3 different embryos. Mean value of different 
sections for each single embryo was used for statistical analysis. 
For mES and primary culture cell quantification cell number per captured field or colony 
number per total number of colonies were counted as indicated in individual graphs.  
Statistical analysis was performed using SPSS /Statistica doing independent sample T- Test 
an non paramaetric Mann Whitney test with a “n” of at least 3 and p-values ≤ 0.05.  
 
5. Results 
 
5.1. Set up of Immunohisto and Immunocytochemistry  
 
In a first attempt, appropriate PFA fixation time, embedding angle thickness of cryostat 
sections and antibody concentrations were determined in CD1 control brain slices of E13.5 
and E14.5 embryos.  
Different antibody concentrations were tested on brain slices cut in different angles, that were 
fixed for different time periods (either four hours or o/n).  
No major differences in the outcome of immunohistochemistry could be observed between 
embryos fixed for o/n or four hours PFA. Therefore fixation time was fixed at four hours.  
A table with determined antibody concentrations is attached in materials and methods.  
Embedding has been optimised to obtain slices that show a similar tyrosine hydroxylase 
expression as seen in Fig. 6 on  immunohistochemical stainings of cryostat mice embryo 
plates taken from Jacobowitz et al. 1998 Chemoarchitectonic Atlas of the Developing Mouse 
Brain [45]A9 and A10 areas of ventral mesencephalon.  
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6) Fig. 6: Ventral mesencephalic dopaminergic neurons of A9 and A10 area  
stained for Tyrosine Hydroxylase (TH) on cryostat sections of (A) E11.5,  (B) E13.5 and (C) E15.5 mouse 
embryos. dnp dorsal noradrenergic pathway, MB mamilary body, RRf retrorubral field, SNC substancia nigra 
compacta, VTA ventral tegmental area. 
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5.2. Set up of optimal primary culture conditions (B27/-B27) 
 
For the determination of optimal primary culture conditions ventral mesencephalic precursors 
have were seeded on culture dishes precoated with only polylysine or culture dishes 
previously treated with polylysine and laminin and in medium with or without (w/o) B27. After 
four days cells have been monitored and phase contrast photos were taken.   
 
 
7) Fig. 7: Phase contrast images of primary culture of dopaminergic precursors from the ventral 
mesencephalon. 
(A) N2 medium supplemented with B27 and wells treated only with polylysine; (B) N2 medium only and wells 
treated only with polylysine; (C) N2 medium supplemented with B27 and wells treated with polylysine and 
laminin; (D) N2 medium w/o B27 and wells treated with polylysine and laminin 
 
 
As can be observed in Fig. 7 cell survival has been found best in culture dishes previously 
treated with polylysine and laminin and seeded in medium containing B27 (Fig. 7C) . 
Therefore these conditions were maintained for further primary cultures.  
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5.3. Analysis of Aralar expression in different experimental models in 
CD1 control mice 
 
5.3.1. Expression in ventral mesencephalon of E14.5 mouse embryos in vivo 
 
So far Aralar expression during embryonic development had not been studied in detail. 
Therefore wild type control embryos (CD1) were screened for Aralar expression in the time 
window of interest, as to say during dopaminergic neurogenesis. As expected Aralar was 
shown to be expressed abundantly in cryostat sections of ventral midbrain of E14.5 mouse 
CD1 control embryos (Fig. 8). 
 
 
8) Fig. 8: Immunohistochemical staining of CD1 ventral mesencephalic cryostat section at E14.5 for 
Aralar at 5x and 10x magnification.  
 
5.3.2. Expression in ventral mesencephalon of CD1 E13.5 mouse embryos in 
primary culture 
 
Also primary culture of dopaminergic precursors derived from embryos at the age of E13.5 
showed abundant Aralar expression in most of the cells including neurons (β-IIItub positive) 
(Fig. 9C). This expression was detected at cytoplasmatic level as could be expected from a 
mitochondrial protein (Fig 9B).The specifity of the antibody directed against Aralar was tested 
as well as can be seen in Fig. 9E.    
 
 
49
 
9) Fig. 9: Immunocytochemistry of primary culture derived from E13.5 CD1 mouse embryos.  
(A) β-III tubulin, Hoechst 40x (B) Aralar, Hoechst 40x (C) Aralar, β-III tubulin, Hoechst merged 40x (D) Aralar, 
Hoechst 20x (E) negative control for secondary antibody Alexa 488 goat α rabbit, Hoechst 20x. 
 
5.3.3. Protein expression in mouse embryonic stem cells (R1 line) in 
proliferation  
 
Furthermore the expression of Aralar during pluripotent state in proliferating mouse 
embryonic stem cells (R1 cell line) was analysed by western blot using mouse embryonic 
feeder cells (MEFs) of CD1 mice as a positive control. Also in this model abundant aralar 
expression could be detected (Fig10).  
 
 
10) Fig. 10: Western blot showing Aralar expression of mES cells  
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5.4. Analysis of ventral mesencephalic dopaminergic neurons during 
embryogenesis in vivo 
 
In order to elucidate a possible implication of Aralar during dopaminergic neurogenesis, 
cryostat sections of aralar (+/+) and aralar (-/-) mice have been obtained and stained 
immunohistochemically. Before comparison of the two genotypes for expression of defined 
markers of dopaminergic neurogenesis, the presence of aralar at the embryonic ages and 
brain area of interest in the used mouse strain has been confirmed (Fig.11).  
 
 
11) Fig. 11: Immunohistochemistry for Aralar in cryostat sections of mouse embryonic midbrain of aralar 
WT mice at different ages 
(A) E11.5 20x; (B) E13.5 20x; (C) E15.5 20x.  
 
For determination of changes in the quantitative outcome of dopaminergic neurogenesis 
Tyrosine hydroxylase expression was studied. Moreover Foxa 2 expression was looked at for 
investigating possible changes in the expression of pro dopaminergic transcription factors, 
that might lead to differences in cell fate programming.To gain insight in possible effects in 
cell cycle activity, expression of Ki67 versus β-III tubulin, a neuronal marker, were studied. 
Evaluation of Ki67 was done by cell counting in a predefined ventral mesencephalic area, 
whereas Foxa 2 and Tyrosine Hydroxilase have been analysed by relative measuremet  of 
expression area against a predefined cropped ventral mesencephalic area.   
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At embryonic day E11.5 no statistical significant differences between knock out (KO) and 
wild type (WT)  mice could be detected neither for TH nor for Foxa. Ki67 has not been 
counted at this age, as almost all cells are positive due to the required proliferative state of 
development (Fig. 12, Graph 1).  
 
II. Graph 1: Quantification of comparative immunohistochemistry of E11.5 ara WT and KO mice.   
(A) TH expression, 10x cropped area 1.3 x1, for graph: values /1000 (B) Foxa2: 10x cropped area 1x1, for 
graph: values /10000.  
 
 
 
 
12) Fig. 12: Immunohistochemical analysis of ventral mesencephalon at day E11.5. 
TH immunoreactivity for WT and KO can be observed in (A) at a magnification of 10x;  Foxa2 
immunoreactivity at 10x in (B); and Ki67/β-III tubuline  immunoreactivity at 10x in (C).   
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At embryonic day E13.5 at first sight aralar knock out slices seemed to show increased TH 
expression, but decreased Foxa2 and Ki67 expression. Still further statistical analysis 
revealed that only decreased Foxa2 expression in aralar knock out mice was statistically 
significant (Fig. 13, Graph 2).  
 
III. Graph 2: Quantification of comparative immunohistochemistry of E13.5 ara WT and KO mice.   
(A)  TH expression: 10x croped area 0.9x 0.55, for graph: x100; (B) Foxa2: 10x cropped area 1x1, for graph: 
/10000 WT: 28,797 +/- 0,65731885, KO: 24,563 +/-  0,14113565, p≤0.003248**  (C) Ki67: 20x not cropped. 
 
 
 
 
 
13) Fig. 13: Immunohistochemical analysis of ventral mesencephalon at day E13.5. (A)  TH in WT and KO 
mice 10x (B) Foxa2 in WT and KO mice 10x (C) Ki67/βIII tub  in WT and KO mice 10x. 
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At embryonic day E15.5 WT sections showed more TH expression in comparison to KO 
sections. This impression could be confirmed as significant by statistical analysis. Decreased 
Foxa 2 expression in aralar knock out sections is also maintained, but only reaches statistical 
significance doing non parametric Mann Whitney test. Moreover statistical analysis revealed 
significantly reduced Ki67 expression in aralar knock out sections at this age (Fig. 14, Graph 
3).  
 
IV. Graph 3: Quantification of comparative immunohistochemistry of E15.5 ara WT and KO mice.   
(A)TH: 5x cropped area 1.3x0.7, for graph: /10000, WT: 15,549 +/- 0,23126728 KO: 12,302 +/- 1,18884, 
p≤0,036472* (B)  Foxa2: 10x cropped area 1.3 x 1, for graph: /10000, WT: 47,409 +/- 4,15435285 KO: 28,709 
+/- 5,395658, p≤0,049535* (Man Whitney) (C) Ki67: 20x not cropped, WT: 36,03 +/- 1,78407773 KO:  25,61 +/- 
2,07896609, p≤0,019045*. 
 
 
 
 
 
14) Fig. 14: Immunohistochemical analysis of ventral mesencephalon at day E15.5. (A)TH 5x (B) Foxa2 5x 
(C) Ki67 5x.  
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5.5. Analysis of ventral mesencaphalic dopaminergic neurons during 
embryogenesis in vitro  
 
5.5.1. Phenotype characterization of WT Ara E13.5 primary culture of ventral 
mesencephalon 
 
Ventral mesencephalon of wildtype aralar embryos was dissected as described in materials 
and methods and cultured for 3 to 4 days in medium containing B27. Then cells were fixed to 
subsequently stain them for proneuronal (β III tubulin), neural (Nestin), glial (GFAP) and 
dopaminergic (Tyrosine Hydroxylase, Foxa, Nurr1) immunocytochemical markers, thereby 
confirming their ventral mesencephalic characteristics (Fig. 15).  
 
V. Graph 4: Quantification of phenotype characterization of primary culture VM E13.5 WT ara  
 
 
 
 
15) Fig.15: Phenotype characterization of WT ara 13.5 primary culture of VM. Immunocytochemistry 
showing expression of (A) TH, βIIItub 40x; (B) TH, Foxa2 40x;  (C) GFAP 40x; (D) TH, Nurr1 40x; (E) TH 
40x; (F) Nestin 40x.  Nuclei were counterstained by Hoechst. 
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Almost no GFAP positive cells could be detected, which confirmed the neuronal character of 
the primary culture. Primary culture of day E13.5 was mainly positive for Nestin, β III tubulin 
and Tyrosine Hydroxylase. Most of the TH positive cells showed also immunoreactivity for 
Foxa2 and Nurr1, which indicates their dopaminergic fate decision (Fig. 15, Graph4). 
 
5.5.2. Confirmation of Aralar expression in WT Ara E13.5 primary culture of 
ventral mesencephalon 
 
Before analysing possible differences in primary cultures between Ara (+/+) and Ara (-/-) 
mice dissections the presence of Aralar in the obtained WT Ara E13.5 primary culture of 
ventral mesencephalon was confirmed doing double immunocytochemistry stainings in 
different cellular subtypes.   
 
 
16) Fig, 16: Immunocytochemistry of WT ara E13.5 ventral mesencephalic primary culture.  
(A) Ara, Nestin 40x; (B) Ara, β-III tub 40x; (C) Ara, TH 40x. Nuclei were counterstained by Hoechst (blue).  
 
Aralar expression in neural cells (positive for Nestin), neuronal cells (positive for , β-III tub) 
and dopaminergic cells (positive for TH) could be confirmed (Fig. 16), suggesting a possible 
role of Aralar in all these cell subtypes.   
 
 
5.5.3. Comparative immunocytochemical study of Ara (+/+) and Ara (-/-) ventral 
mesencephalic primary cultures (E13.5 and E14.5) 
 
In order to do a comparative immunocytochemical study between Ara (+/+) and Ara (-/-) 
primary cultures ventral mesencephalic regions of respective E13.5 and E14.5 embryos have 
been dissected and cultured for 4 days. Afterwards cultures have been fixed for subsequent 
immunocytochemistry.  
To gain insight in possible changes in cell death (apoptosis) and cellcycle activity expression 
of Ki67 and Caspase3 respectively were studied. Morevover β-III tubulin expression was 
looked at for investigating possible switches from neuronal to glial identity. Tryptophane 
hydroxylase was also applied, for excluding the possibility of differentiation into serotonergic 
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cells. TH expression was used to determine changes in the quantitative outcome of 
dopaminergic neurogenesis. 
 
VI. Graph 5: Quantification of comparative immunocytochemistry of VM primary culture of WT and KO ara 
mice at E14.5  
(A) TH: WT:6,7+/-0,86922699 KO:3+/-1,41210751, p≤0,00484 ** (B) β III tub (C) Ki67:  WT: 7,3+/-1,34989712 
KO:20,3 +/- 2,56255081, p≤0,000053***.   
 
 
 
 
17) Fig. 17:  Comparative immunocytochemistry of ventral mesencephalic primary culture WT and KO ara 
at E14.5  
(A) WT TH, βIII tub 40x (B) KO TH, βIII tub 40x (C) WT Ki67 40x (D) KO Ki67 40x. Nuclei were 
counterstained by Hoechst (blue).  
 
 
Ventral mesencephalic primary culture from embryonic day E14.5 revealed statistical 
significantly decreased TH expression in ara KO, β-III tub expression showed to be equal in 
ara WT compared to KO. Moreover cycling as shown by Ki67 stain was statistically 
significantly increased in ara KO cell cultures.  
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In a next step ventral mesencephlic primary culture at E13.5 was obtained, to obtain more 
insight into possible cellcycle differences that could lead to this outcome.  
 
VII. Graph 6: Quantification of comparative immunocytochemistry of VM primary culture at E13.5 
(A) TH (B) Casp3: WT:1,3+/-0,44095855 KO: 7,7+/- 1,09290642, p≤ 0,000386**; (C) Ki67 WT: 5,5 +/ 
1,44337567 KO: 27,83 +/- 1,42400062, p≤ 0,005792**. 
 
 
 
 
18) Fig. 18: Comparative immunocytochemistry of ventral mesencephalic  primary culture  WT and KO 
ara at E13.5  
(A) WT TH 40x (B) KO TH 40x (C) WT Ki67 40x (D) KO Ki67 40x (E) WT Casp3 40x (F) KO Casp3 40x. 
Nuclei were counterstained by Hoechst (blue).   
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Also at embryonic day E13.5 statistically significantly elevated cell cycling as shown by Ki67 
could be observed. Furthermore aralar knock out primary culture Casp3 activity significantly 
exceeded Casp 3 activity in wild type primary culture. For TH no statistically significant 
differences could be detected, still a trend to reduced TH expression in KO primary culture 
was observed (Graph 6). Almost no Tryptohphane positive cells could be observed neither in 
WT nor in ara KO primary culture (Fig. 18).  
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5.6. Mouse embryonic stem cell lines from Ara (+/-) mice 
 
5.6.1. Generation of embryonic stem cell lines from Ara (+/-) 
 
For obtaining wild type aralar and knock out aralar mouse embryonic stem cell lines 
heterozygoteous animals had to be mated, as knock out animals are not viable longer then 
20 days. Therefore a modified protocol of Bryja et al. 2006 [44], was followed. From 3 
pregnant females which permitted the extraction of 18  blastocysts 12 stable cell lines could 
be established (70% success). 
 
5.6.2. Determination of Genotype of established cell lines  
 
PCR 
These cell lines have been grown on feeder free culture dishes for various passages to get 
rid of mouse embryonic fibroblast cells and were then genotyped.  
First DNA extraction followed by PCR for amplifying the knocked out and the wildtype 
sequence revealed only wild type bands in agarose gel electrophoresis (Fig. 19 A). This 
seemed very unprobable as usually a ratio of 5:5:10 for (-/-), (+/+) and (+/-) aralar 
respectively is reached. PCR was repeated, but lead to the same outcome (Fig. 19 B).  
A possible resting contamination with MEF feeder layer cells which would have contained 
wild type aralar could have led to this result. As the wild type sequence is shorter and easier 
amplified by PCR the primers could have been used up for amplification the wildtype 
fragment. That is why after passaging cells again on gelatin another DNA extraction and 
genotyping was done. Also this second attempt failed to generate any knock out fragments 
(Fig. 19 C).  
After passaging the lines one more time and doing another DNA extraction the PCR reaction 
has been split into two, one set of the 12 lines was amplified with only the primers for the 
knock out fragment and the other set of lines was amplified with only the primers for the wild 
type fragment. Like this the different fragments do not compete for their common primer.  
Also these separated PCR reactions amplified only wild type fragments (Fig. 19 D,E).  
The wild type genotype has been confirmed as well by Western blot analysis. All the 12 lines 
showed weak but persistent signals for the wild type proteins in Western blot. As at first sight 
one line (line 15, termed Neo) seemed to survive neomycine selection (explained later on), 
its cell lysate was included in the third DNA extraction, but it also turned out to produce only 
the wildtype protein upon PCR amplification, and failed to survive in a repetition of 
neomycine selection (Fig. 19 D,E). 
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19) Fig. 19: Gelelectrophoresis of PCR Genotyping of established blastocyst lines 
(A) First  DNA extraction first PCR attempt (B) repetition of PCR (C) second  DNA extraction after additional 
passage of cell lines on gelatine (D) third  DNA extraction after another passage of cell lines on gelatine, 
PCR with ara WT primers only (E) third DNA extraction after another passage of cell lines on gelatine, PCR 
with ara KO primers only.  
Western Blot  
All twelve lines were analysed for the presence of wild type aralar by Western blot. Using this 
approach a possible contamination by MEF Ara protein would have been undetectable.  
 
 
20) Fig. 20: Western blot of twelve derived blastocyst lines showing Aralar bands (74 kDa), marker (M). 
 
All the 12 lines showed weak but persistant expression signals for the wild type protein aralar 
in Western blot and thereby confirmed their wild type genotype (Fig. 20). 
 
Neomycine selection  
 
The original Aralar mouse transfection vector contained a G418 neomycine resistance. 
Therefore knock out cells as also heterozygotus cells should survive G418 selection.  
So in a last attempt the twelve cell lines were seeded in the presence of 500 µg/ml G418 in 
SRM containing LIF, after four days concentration of the antibiotic was reduced to 250 µg/ml.  
Although at first sight line number 15 seemed to resist the selection after 8 days practically 
all cells were dead. A second selection  (data not shown) starting with 250 µg/ml G418 right 
away did not lead to any surviving cell line either after 8 days of culture with the antibiotic.  
None of the twelve lines survived neomycine selection which confirms furthermore that no 
heterozygoteous line could be established (Fig. 21). 
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21) Fig. 21: Phase contrast images of twelve derived blastocyst lines in neomycine selection 
(A) cell lines in control medium SRM + LIF after four days proliferation (B) cell lines in medium SRM + LIF 
containing 500 µg/ml G418 (C) cell  lines in medium SRM +LIF containing four days 500 µg/ml G418 and four 
days 250 µg/ml G418. 
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5.6.3. Characterization of two Ara (+/+) versus one mES control cell line in 
proliferation 
 
The pluripotent characteristics of two of the established lines, number six and number seven, 
have been explored in comparison to the comercial E14 mES line. Therefore cells have been 
fixed after culturing them in SRM medium containing leukemia inhibitory factor and checked 
for the expression of pluripotent markers Sox 2, Oct 4 and the SSEA1. Cytochemistry for 
alkaline phosphatase has also been done. All cell lines have been analysed for Aralar 
expression in proliferation. 
 
VIII. Graph 7: Quantitative comparison of pluripotency markers between E14, L6 an L7 cell lines in 
proliferation (A) Sox2 (B) Oct4.  
 
 
 
Pluripotency could be confirmed by cell counting of the markers Sox2 and Oct4. All three 
lines showed more than 95% of positive cells for pluripotent markers, Oct4 slightly excelling 
Sox2 expression percentage. 
Aralar expression could be confirmed in all three cell lines by immunocytochemistry (Fig. 22). 
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22) Fig. 22: Immunocytochemistry and Cytochemistry of E14, L6 and L7 mES in proliferation  
(A)Sox2 (B) Oct4 (C) SSEA1 (D) Alkaline phosphatase (E) Aralar. Nuclei were counterstained by Hoechst 
(blue). 
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 of differentiation 
ctors to follow the time course of differentiation. Then immunocytochemistry was performed 
L6 seems to express slightly more Nestin and β-III tubulin (Fig. 23 A,B,D,E).  
oth cell lines show consistent Aralar expression throughout differentiation (Fig.  23 C,F, Fig. 
24 C,F, Fig 25).  
 
5.6.4. Differentiation of two Ara (+/+) versus one mES control cell line 
 
The same two lines have also been characterized for their differentiation capacity towards a 
dopaminergic fate in comparison to the commercial E14 mES cell line. Therefore the cells 
were seeded at single cell densities on PA6 feeder layers, LIF was withdrawn and 
differentiation factors have been added according to a slightly modified differentiation 
protocol from Barberi et al. 2006 [11] as described in materials and methods. Some wells 
have been fixed at each differentiation step as to say before each change
fa
for the following markers:  Aralar, Nestin, β-III tubulin, Sox2, TH, and Oct4.  
 
Both cell lines still showed pluripotent properties at day 5 of differentiation expressing Sox2 
and Oct4, but started already expressing Nestin which means that they become neural 
precursors. At day 5 so far no TH positive could be detected. Yet at day eight of 
differentiation both lines started expressing TH at the borders of the colonies as a sign of 
obtaining dopamineric characteristics. Also βIII tubulin expression augments from day five to 
day 8 at the periphery of colonies, whereas remaining Sox2 and Oct4 expression gets more 
and more restricted to centers of colonies, where cells are supposed to maintain their 
pluripotent state. 
B
 
23) 
(A) E14 Nestin, Aralar 20x  (B) E14 Oct4, βIII tubulin 20x (C) E14 Sox2, TH 20x (D) L6 Nestin, Aralar 20x  (E) 
L6 Oct4, βIII tubulin 20x (F) L6 Sox2, TH 20x. Nuclei were counterstained by Hoechst (blue).  
Fig. 23: Immunocytochemistry of time course of dopaminergic differentiation E14 and L6 mES cells at 
day 5 of differentiation 
 
24) Fig. 24: Immunocytochemistry of time course of dopaminergic differentiation E14 and L6 mES cells at 
day 8 of differentiation. 
(A) E14 Nestin, Aralar 40x (B) E14 Oct4, βIII tubulin 20x (C) E14 Sox2, TH 40x (D) L6 Nestin, Aralar 40x (E) 
L6 Oct4, βIII tubulin 20x (F) L6 Sox2, TH 40x. Nuclei were counterstained by Hoechst (blue). 
 
 
25) Fig. 25: Comparative immunocytochemistry of finally differentiated  mES cell lines E14, L6 and L7 
(day 13) 
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6. Discussion 
 
Parkinson`s disease (PD) is characterized by a progressive loss of of dopaminergic neurons 
(DAn) of SNpc. At the moment, no sufficiently effective treatment options for this disease are 
available. Still one possible therapy research has advanced quite significantly on, is cell 
therapy. As the usage of fetal tissue as a cell source is associated with ethical and low 
availability problems, research has shifted its interest on alternative cell sources like ES cells. 
Still one major problem that has to be overcome is poor dopaminergic differentiation cell 
harvest. Therefore it is necessary to study all possible influencing factors on dopaminergic 
neurogenesis.   
Aralar, a mitochondrial glutamate/aspartate carrier, belongs to the family of CaMs and is 
member of the MAS NADH shuttle. Aralar has been shown essential for proper mitochondrial 
function[1]. 
Having in mind that differentiating neurons have increasing energetic demands, that 
differentiating neurons produce elevated levels of ROS, which could underlie mitochondria to 
an increased stress, and that the MAS shuttle function could be implied in differentiation 
abilities of cells the matter arises whether Aralar could be relevant for cell differentiation and 
for its survival capacity.   
The aim of this thesis was to elucidate possible implications of Aralar in dopaminergic 
neurogenesis.  
Aralar expression studies carried out in CD1 aralar wild type mice enforced the suspicion of 
its implications, as different experimental methods revealed that it is expressed in critical 
phases of dopaminergic neurogenesis.  Immunohistochemical analysis in ventral 
mesencephalon of E14.5 mouse embryos (Fig. 8,9) , immunocytochemical analysis  in E13.5 
VM primary culture and Western blot of proliferating R1 mES cells (Fif. 10) confirmed 
abundant Aralar expression throughout embryonic development. Also immunohistochemistry 
of ara wildtype VM cryostat sections at ages E11.5, E13.5 and E15.5 was consistent with 
these findings (Fig. 11). 
 
 
Comparative in vivo immunohistochemical expression studies of VM cryostat sections 
of WT(+/+) and KO (-/-) Aralar embryos revealed no statistical differences for neither TH nor 
Foxa2 at embryonic age E11.5 (Fig. 12) (Graph 1), probably because this stage of 
dopaminergic neurogenesis is too early for evaluation of any manifestation of differences in  
dopaminergic harvest by TH expression. At E13.5 first differences in Foxa2 expression can 
be observed, the decreased Foxa2 expression in ara knock out embryos at E13.5 (Fig. 13) 
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(Graph 2) is maintained in E15.5 (Fig. 14) (Graph 3) sections which already points to 
changes in dopaminergic neuron harvest. Experiments of Ferri et al. [29] have shown that 
decreased Foxa2 expression does not lead to changes in proliferation or cell death, but 
rather cause a change in fate decision.   Indeed at E15.5 TH expression is statistically 
decreased in aralar kock out embryos.  This could mean that a fate switch to gabaergic 
neurons is occurring, which will be interesting to explore in future experiments.  
Moreover ara KO mice sections at E15.5 show less Ki67 expression (Fig.14) (Graph 3), this 
could be due to a generally enhanced cell mortality of precursors as an alternative to the 
proposed fate switch.  
 
Comparative in vitro immunocytochemical expression studies of characteristic 
dopaminergic markers as well as cellular markers in primary culture of E13.5  dopaminergic 
precursors of the ventral mesencephalon of WT(+/+) and KO (-/-) Aralar embryos revealed 
that at embryonic day E13.5  (Fig. 17, Graph 6) cell cycling as shown by Ki67 expression 
levels was statistically significantly elevated in knock out aralar primary culture in comparison 
to wild type primary culture.  
Furthermore percentage of Casp3 positive cells in aralar KO primary culture statistically 
significantly exceeded percentage of Casp3 positive cells in ara WT primary culture. 
Although the in vitro model can never be directly compared with the in vivo model an 
elevated cell death at E13.5 could explain why at E15.5 less Ki67 can be detected in tissue 
expression studies. For TH no differences could be detected (Fig. 17, Graph 6) which is 
consistent with in vivo findings. 
Ventral mesencephalic primary culture from embryonic day E14.5 maintained statistical 
significant differences in Ki67 expression (Fig. 18, Graph 5), showing more expression in ara 
KO cells. Moreover TH expression was statistically significantly decreased in ara KO primary 
culture at E14.5.   
One possible explanation could be higher ROS production as a consequence of impaired 
mitochondrial function during increasing energy demands for the differentiating precursors. 
Increased hematopoietic stem cell (HSC) ROS levels have been associated with lowered 
self-renewal, increased cell cycling and reduced HSC and progenitor viability [46].  
When putative stem cells isolated from the retina were exposed to oxidative stress in vitro, 
the response of Muller cells was to increase proliferation and dedifferentiation [43].  
So although first there are as much differentiating and differentiated cells in ara KO as in ara 
WT later elevated cell death occurs in ara KO. The dividing Ki67 positive cells might die, or 
might go back to a pluripotent state with lower ROS production 4 in which cells divide more 
and do not exit cell cycle is an attempt to compensate increased cell death.  
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Almost no Tryptohphane positive cells could be observed neither in wild type nor in ara 
knock out primary culture of E13.5, which confirms their ventral mesencephalic identity and 
shows that at least no fate switch towards a serotonergic fate occurs.  
Β-III tubulin expression showed no differences between ara WT compared to KO in E14.5 
primary culture, which could be interpreted as no change towards a glial fate has taken 
place.  
 
The derivation mES cell lines from blastocytes of E3.5 ara (+/-) mice mated mice led to the 
establishment of twelve mES cell lines. Two of these lines (line 6 and line 7) have been 
checked for their pluripotency by immunocytochemistry and cytochemistry comparing them 
to a commercially available mES cell line E14.  
Sox2 and Oct4 positive cell counts exceeded in all three cases 95% of total cells, validated 
by Hoechst staining, which confirms their pluripotency. Slight differences between cell lines 
like lower Sox2  and Oct 4 percentages in L6 compared to line 7, could be explained by 
different seeding densities, which can influence their uninduced muted, light, starting 
differentiation at some cell colony boarders (Fig. 22) (Graph 7). 
 
Furthermore when differentiation was induced applying a modified protocol from Barberi et 
al.  [11] the lines were able to give rise to dopaminergic neurons to an expectable extend 
(Fig. 25).  Following the time course of differentiation comparing L6 to L7 the expression of 
Sox2 and Oct4 slowly diminished from day 5 on whilst a lot of Nestin positive neuronal 
precursors could be seen (Fig. 23) whereas at day eight first TH positive cells could be 
observed at the boarders of colonies(Fig. 24).  During this differentiation process Aralar 
showed consistent expression, which lead to the assumption that it is needed throughout the 
whole process. It is implausible that Aralar was indispensable for differentiation as 
immunohistochemical and immunocytochemical studies around the embryonic age of  E13.5 
showed that dopaminergic neurons were present, if also to lesser extend, in ara (-/-) animals. 
Still some impact seems very probable and will have to be investigated by comparative 
WT(+/+) and KO (-/-) mES cell studies.  
 
Abundant Aralar expression could be observed (Fig. 22) in all 3 proliferating mES cell 
lines.  
This observation is contradictory if one considers that in pluripotent mES the mitochondrial 
network is poorly developed, cells containing small numbers of inmature mitochondria. 
Therefore a smaller number of mitochondria would have to express Aralar even in a higher 
extend. The question remains which role Aralar could have at that point.  
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At the two-cell and eight-cell stages of blastocysts there is increased activity of the MAS in 
vivo and in vitro, which enables the transport of reducing equivalents across the 
mitochondrial membrane, thereby maintaining the redox balance between the cytoplasm and 
mitochondria and enabling the use of lactate and glucose as energy substrates [47].   
ICM cells of the blastocyst have been shown previously to rely entirely on aerobic glycolysis 
for their energy requirements, converting 100% of the glucose taken up to lactate [48] which 
doesn´t need MAS shuttle activity.  
On the other hand trophectoderm (TE) cells generate a significant proportion of their energy 
from oxidation, approximately 55% [48].  Mitchell et al. conclude that MAS dysfunction would 
mediate its effects on embryonic development in these very early stages via TE [49].  
But maybe a difference in energy metabolism between ICM as part of a blastocyst and mES 
cells in proliferation in vitro, does exist, as to say, ICM might perform basically aerobic 
glycolysis and mES  might use mainly lactate conversion to pyruvate by lactate 
dehydrogenase which needs elevated NADH recycling. 
 
It was not possible to derive any knock out blastocyst line from heterozygotus aralar 
mice.  
Among twelve embryonic stem cell lines that were established not even one turned out to be 
heterozygoteous or  completely deficient for agc1, although mating of Het x Het mice usually 
results in a ratio of (+/-):(-/-):(+/+)  49:25:26 [1] The obtained genotypes have been confirmed 
by 3 different methods: westernblot (Fig. 20), genotyping via PCR (Fig. 19) and neomycin 
selection (Fig. 21).  
This lead to the conclusion that Aralar might already be implicated at a very early point of 
development maybe because of restricted energy supply. 
Studies using a AOA as a MAS inhibitor showed that eight –cell embryos developed to the 
blastocyst stage at high rates, but numbers of cells were significantly reduced in these 
conditions [49]. Hence one could conclude that at day 3.5 when blastocysts are collected it is 
only possible to collect WT blastocysts as KO and HET blastocysts are growth retarded and 
therefore hardly detectable. 
 
The question remains whether  Aralar is really indispensable for energy supply or it 
rather carries out its main function by its requirement for N-acetyl Aspertate 
production?  
 
Recently Wibom et al. [50] have reported a case of a female child patient having a non 
functional mutated form of AGC1 who suffers from severe muscular hypotonia and 
psychomotor retardation affecting mainly motor skills. Magnetic resonance investigations 
showed global cerebral hypomyelination. However the patient had no substantial 
accumulation of lactate detected on magnetic resonance spectroscopy, which is considered 
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a marker for impaired oxidative phosphorylation. These findings do not support compromised 
neuronal energy production by the respiratory chain as a major pathogenetic mechanism in 
AGC1 deficiency, suggesting that the malate-aspartate shuttle may not be bioenergetically 
essential in the central nervous system. The glycerol-3-phosphate cycle, known to be active 
in the brain, is an alternative pathway of transfer for reducing equivalents into the 
mitochondria. The hypomyelination in the patient was confined to the cerebral hemispheres, 
with findings essentially normal in the cerebellum and brainstem. The ontogeny of tissue 
specific expression of AGC1 in the human central nervous system is unknown, and residual 
expression of AGC2 may explain the regional differences seen in the patient. [51].   
Mitochondrial shuttle activity decrease in Aralar deficient mouse embryos can already be 
observed prenatally (around E15, unpublished data Beatriz Pardo), which means that Citrine 
is not fully able to compansate for Aralar during mouse embryonic development at this stage. 
Whether at that point Citrine expression gets already restricted to the periphery and therefore 
the mitochondrial dysfunction is due to a dose dependent decrease in Citrine or Citrine does 
not compensate at all but has another role in embryonic development still has to be 
determined.  
Future studies will also have to expand the in vivo experiments to a postnatal stage exploring 
the time course of TH expression and other markers. Moreover it will be essential to derivate 
ara (-/-) mES cell lines or as an alternative knock down Aralar expression in the already 
established lines by RNAi, for observation of energetic and metablic changes that could lead 
to restrictions in differentiation capacity.  
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Zusammenfassung 
 
Aralar, ein mitochondrialler Aspartat /Glutamat Transporter, zählt zur Familie der Calcium 
mitochonriellen carrier und ist eine grundlegende Komponente des Malat-Aspartat NADH 
shuttle (MAS). Das Protein ist unerlässlich für eine einwantfreie Funktion der 
Mitochondrien[1].  
Berücksichtigt man, dass differenzierende Neuronen einen erhöhten energetischen Aufwand 
haben, dass diese dadurch auch mehr ROS produzieren, welche die Mitochondrien einem 
größerem Stress aussetzten[2] and dass die MAS shuttle Funktion eventuell einen Einfluss 
hat auf die Fähigkeit der Neuronen sich zu differenzieren bzw. zu überleben[3], stellt sich die 
Frage ob Aralar möglicherweise eine Relevanz für Zelldifferenzierung beziehungsweise 
Zellüberleben hat. 
 In dieser Diplomarbeit wurde der etwaige Einfluss von Aralar auf dopaminerge Neurogenese 
untersucht.  
Unter der Verwendung von Immunohistochemie  in Cryostat Schnitten des ventralen 
Mesencephalons (VM), Immunocytochemie in  Primärzellkultur des VM und mES Zellen und 
Western Blot Methoden, durchgeführt in CD1 Wildtyp Mäusen konnte eine abundante Aralar 
Expression während kritischer Phasen dopaminerger Neurogenese bestätigt werden. 
Vergleichende immunohistologische and immunocytochemische Studien des VM im 
embryonalen Alters von E11.5, E13.5, E14.5 und E15.5 von WT(+/+) und KO (-/-) Aralar 
Mäusen deckten Differenzen der quantitativen Ernte an dopaminergen Neuronen (erhoben 
anhand TH expression) und Unterschiede der Expression des dopaminergen 
Transkriptionsfaktors Foxa2, wie auch des Zellcyklus Marker Ki67 und des apoptotischen 
Markers Casp3 auf. Eine mögliche Erklärung wäre ein Einfluss von Aralar auf die 
Zellüberlebenskapazität auf Grund von fehlender mitochondrieller Integrität. Darüber hinaus 
könnte das Abhandenkommen der MAS shuttle Aktivität metabolische Veränderungen 
hervorrufen und dadurch die Transkriptionskontrolle der dopaminergen Neurogenese 
beeinflussen.  
Des Weiteren wurden mES Zelllinien durch aralar (+/-) Kreuzungen erzeugt und 
charakterisiert. Die Pluripotenz der Linien konnte durch Immunocytochemie und Cytochemie 
bestätigt werden. Genotypierung, antibiotische Selektion und Western Blot Analyse zeigten 
jedoch, dass keine Aralar defiziente Linie unter den hergeleiteten Linien war. Daraus wurde 
geschlossen, dass Aralar bereits zu einem sehr frühen Zeitpunkt der Entwicklung eine Rolle 
spielt, vielleicht auf Grund restringierter Energiebereitstellung durch defekte Mitochondrien. 
Aralardefizienz im Blastocystenstadium könnte deren Detektierung erschweren.   
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